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Funksjonell genomforskning og hjertesvikt: 
Fra teknologi til fysiologi 
 
Hovedmålet for prosjektet var å identifisere molekylære mekanismer assosiert med 
økning av hjertestørrelse (hypertrofi) som følge av sykdom. Dette ble oppnådd ved 
blant annet å utvikle, etablere og benytte DNA mikromatriseteknologi og tilhørende 
dataanalysemetoder. Mikromatriseanalyser gjør det i prinsippet mulig å måle 
mengden mRNA (genutrykk) for alle genene i et genom (en organismes totale 
arvemasse) samtidig, i ett enkelt forsøk. 
Hjerteprøver fra pasienter med hjertesvikt på grunn av koronar hjerte sykdom 
(blokkering av kransarterie som blant annet gir hjerteinfarkt) og sykdom i selve 
hjertemuskelen (kardiomyopati) ble undersøkt. Mikromatriseresultatene viste 
sykdomsspesifikke mønster, i hovedsak knyttet til stoffskifteprosesser, nedbryting og 
regulering av signalmolekyler. Det ble videre utviklet klassifikatorer (et sett med 
regler), basert på genuttrykks data fra mikromatriseanalysene. Klassifikatorene ble så 
brukt for å kunne forutsi om en ”ukjent” prøve kom fra en pasient med koronar hjerte 
sykdom eller fra en pasient med kardiomyopati. Disse forsøkene viser at i fremtiden 
vil slike metoder og teknologi muligens kunne bli brukt ved diagnostikk av 
hjertesykdom. I eksperimentelle rottemodeller, ble det så identifisert hittil ukjente og 
allerede kjente molekylære mekanismer assosiert med hjertehypertrofi indusert ved 
trening og hypertrofi indusert ved koronar hjertesykdom. Resultatene viste blant annet 
at ved sykdomsindusert hypertrofi blir gener assosiert med fettsyrestoffskiftet i 
hovedsak nedregulert. Dette skjer imidlertid ikke ved treningsindusert hypertrofi, noe 
som ser ut til å være en viktig forskjell mellom disse typene hypertrofirespons. 
Treningsindusert hypertrofi ble videre assosiert med mindre endringer på 
genuttrykksnivå, enn ved hva som ble observert ved koronar hjertesykdom. Dette 
indikerer at regulering på andre nivåer enn transkripsjon og genregulering, for 
eksempel fosforylering på protein nivå, kan være en viktig faktor ved treningsindusert 
hypertrofi. En av delstudiene viste at H+/K+ ATPase (protonpumpe) er uttrykt og 
regulert på mRNA og protein nivå i både hjerteceller og hjertevev. Studier av levende 
hjerteceller indikerte videre at H+/K+ ATPase kan stå for opp mot 25% av 
kaliumopptaket over cellemembranen. Dette indikerer at proton pumpen kan være en 
viktig mekanisme for pH- og kaliumregulering. 
En viktig del av prosjektet var utvikling og bruk av programmet GeneTools, et ”alt i 
ett annoteringsverktøy”. GeneTools består av informasjon fra eksterne databaser 
(blant annet Entrez, Gene Ontology og SwissProt) samt at brukeren kan legge til og 
lagre egen definert informasjon. Videre inneholder GeneTools verktøyet eGOn, som 
tilbyr statistiske tester for å identifisere over/underrepresentasjon av sett/klasser med 
gener basert på informasjon om deres biologiske funksjon. Programmet er allerede 
blitt meget populært (>2000 brukere fra >50 land) på grunn av sin funksjonalitet og 
enkelt brukergrensesnitt. 
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Summary 
 
Genome wide gene expression in cardiac disease is incompletely characterized. The main 
purpose of this project was to increase insight into molecular mechanisms of myocardial 
hypertrophy and heart failure in experimental models and human disease. We aimed to 
establish and use microarray technology and bioinformatics tools to obtain these results. 
Finally, we sought to relate gene/protein expression to function in vitro, by functional studies 
in isolated cardiac myocytes. 
Microarray technology and methods of data analysis were established which enabled detection 
of differentially expressed genes. Combining gene expression data and functional annotations 
yielded a biologically meaningful analysis which identified potentially important molecular 
mechanisms of end-stage heart disease and physiological hypertrophy. Gene expression 
classifiers were developed to distinguish between myocardial samples from end-stage heart 
failure, originating from either coronary artery disease or dilated cardiomypathy. Gene-class 
testing analysis indicated aetiology-specific patterns in coronary artery disease and dilated 
cardiomypathy, primarily related to genes involved in catabolism and regulation of protein 
kinase activity. Serial cardiac-specific gene expression was studied during the development of 
hypertrophy in congestive heart failure and exercise training. Our results suggest that one of 
the main molecular differences could be down-regulation of fatty acid metabolism genes, 
which was observed in pathological hypertrophy but not in exercise-induced hypertrophy. 
Congestive heart failure was associated with more comprehensive changes in gene expression 
than exercise training. This indicates that post-transcriptional and post-translational regulation 
may be important in physiological hypertrophy. All gene/protein annotations and gene-class 
analyses were generated by GeneTools, a program that was developed in our group during the 
project as an “all in one” annotation tool. 
In isolated rat ventricular cardiomyocytes, we showed that H+/K+-adenosine triphosphatase 
was expressed and regulated both at the transcript and protein level. Functional in vitro studies 
indicated that the H+/K+-ATPase may account for up to about 25% of the K+-uptake across the 
ventricular sarcolemma. 
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1. Introduction 
 
1.1 Cardiovascular disease 
Heart failure is a common end stage of cardiovascular disease and a leading cause of death 
worldwide [1]. However, in the recent years the “omics” technologies have resulted in new 
knowledge in cellular and molecular biology and have improved the understanding of the 
mechanisms of the disease and the possibility to design highly specific efficient drugs and 
other treatment strategies. In this way detailed knowledge of the basic mechanisms of heart 
failure has been and will be of vital importance and an important field of intensive research. 
 
1.1.1 Heart failure pathophysiology 
When a person is diagnosed with heart failure (HF), it does not mean the heart has stopped 
working, but rather that it is not working as efficiently as it should [2]. HF may occur 
suddenly, or it may develop gradually. When heart function deteriorates over years, one or 
more conditions may exist. The strength of muscle contractions is reduced, and the ability of 
the heart chambers to fill with blood may be limited by mechanical problems, resulting in less 
blood to pump out to tissues in the body. Conversely, the pumping chambers may enlarge and 
fill with too much blood when the heart muscle is not strong enough to pump out all the blood 
it receives [3]. In terms of histology, four features define the failing heart: myocyte 
hypertrophy, fibrosis, “slippage” of the previously orderly aligned myocytes which 
presumably leads to inefficient contraction, and apoptosis of myocytes. Together these 
processes are termed “remodeling” [4]. 
 
1.1.2 Causes 
Several different issues can cause HF. The main cause is coronary artery heart disease (CAD) 
causing insufficient blood supply to the myocardium. CAD is usually caused by 
atherosclerosis, which is associated with the aggregation of lipids or plaque on the walls of the 
arteries. Then the heart’s ability to perform decreases, because ischemia results in the delivery 
of less oxygen and nutrients to the heart muscle [5]. 
Cardiomyopathies are primary or secondary disorders of cardiac muscle associated with 
abnormal cardiac wall thickness, chamber size, contraction, relaxation, conduction, and 
rhythm. They are a major cause of morbidity and mortality at all ages and, like acquired forms 
of cardiovascular disease, often result in HF. There are three major types of cardiomyopathy, 
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dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and restrictive 
cardiomyopathy (RCM) [6]. Causes of cardiomyopathy include infection, alcohol abuse, and 
cocaine abuse. However, cardiomyopathies are frequently hereditary and therefore subject to 
genetic studies. DCM can e.g. be caused by mutations at 25 chromosome loci where genes 
encoding contractile, cytoskeletal, and calcium regulatory proteins have been identified [7]. 
Long-standing high blood pressure (hypertension) is another common cause of HF and results 
in an increased heart muscle mass, especially of the left ventricle. In this way, left ventricular 
hypertrophy (LVH) is the most potent predictor of adverse cardiovascular outcomes in the 
hypertensive population, and an independent risk factor for coronary heart disease, sudden 
death, heart failure and stroke [8]. 
 
1.1.3 Treatment 
Whenever possible, the best treatment of HF is one of prevention. This includes diagnosing 
and treating high blood pressure and attempting to prevent atherosclerosis [9,10]. A prudent 
diet, regular exercise, and weight control are also important [11]. When a patient is diagnosed 
as having HF, the first treatment is often restriction of dietary sodium. Diuretics help the 
kidneys to get rid of excess water and sodium, thereby reducing blood volume and working 
load of the heart [10]. Drugs for the treatment of HF include vasodilators, which cause the 
peripheral arteries to dilate. Standard vasodilators used for HF are the angiotensin-converting 
enzyme (ACE) inhibitors. ACE inhibitors block the production of angiotensin II (ANG II), a 
potent constrictor of blood vessels. Several landmark studies have demonstrated the 
effectiveness of long term treatment with ACE inhibitors in reducing the risk of death [12-14]. 
Other drugs used in the treatment of HF include beta blockers, which slow the heart. In the 
1970s and 1980s beta blockers were commonly used on patients with HF, but mixed effects 
were shown. However, studies in the 1990s and later showed reduce risk of death with use of 
β-receptor antagonists, and combined treatment with ACE-inhibitors reduces mortality even 
more [15,16]. In addition to prevention and drugs, sometimes surgery proves effective. For 
example when HF is due to valvular disease, surgical implantation of an artificial heart valve 
or valve repair may relieve the problem [17]. Coronary artery bypass graft surgery [18] and 
coronary catheterization using balloon dilatation [19] are among the therapeutic techniques 
used to prevent and treat HF caused by blocked arteries. Heart transplants are a last resort in 
treating severe HF caused by diseased heart muscle. However, the cost of the operation and 
the shortage of donor organs make it impractical except as a last resort [20]. 
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A new treatment of HF in the future might be cardiac stem cell therapy, which recently has 
raised many hopes. However, neither the ideal source and type of stem cell nor the critical cell 
number and mode of application have been defined so far [21]. 
 
1.1.4 Cardiac hypertrophy 
Cardiac hypertrophy is an adaptive physiological response to increases in blood pressure that 
preserves myocardial wall stress, chamber size and contractile function. Despite these initial 
advantages, cardiac hypertrophy is also an independent risk factor for cardiovascular disease 
and, if left untreated, it frequently progresses to HF. In broad terms, there are three types of 
cardiac hypertrophy: normal growth, growth induced by physical conditioning (physiological 
hypertrophy), and growth induced by pathologic stimuli (pathological hypertrophy). 
 
1.1.4.1 Relation of cardiac hypertrophy and heart failure 
Clinically, the term “pathological” hypertrophy is used and referred to as an abnormal increase 
in cardiac mass, usually by an increase in the size of cardiac myocytes and an increase in the 
number of the fibroblasts and other cells. Precisely defined, hypertrophy exclusively refers to 
an increase in the volume of cardiac muscle cells. 
Pathologic hypertrophy of cardiac myocytes is often a precursor of HF, and therefore research 
on the molecular pathways leading to hypertrophy can be considered as research into the 
initial step of HF [22,23]. It is also important to note that the molecular composition of the 
failing heart is relatively uniform and largely independent of the initiating injury or disease, as 
also described in Study II and IV. 
The two major pathological stimuli for hypertrophy are mechanical stress and neural/humoral 
factors, which activate intracellular signaling pathways resulting in altered gene expression 
and protein synthesis, leading to an enlarged heart [24]. It has long been thought that 
“pathological hypertrophy” with fibrosis, occurring in hypertension and HF, is a useful 
adaptation of the heart to increased load, by analogy to the situation in athletes, who have 
“physiological hypertrophy” without fibrosis. This view has recently been changed and today 
it has been postulated that it is not hypertrophy per se that is detrimental but rather the balance 
of different signal pathways [25]. However, it remains true that pathological hypertrophy in 
humans is a frequent precursor to HF [26]. 
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1.1.4.2 Physiological hypertrophy induced by exercise 
Chronic exercise training can cause cardiac hypertrophy and is commonly referred to as “the 
athlete’s heart” [27]. The athlete’s heart is a physiological cardiac hypertrophy that is 
characterized by increases in left ventricle (LV) chamber size, wall thickness, and mass. 
Because the ratio of LV wall thickness to radius is unchanged, the athlete’s heart is classified 
as eccentric LV hypertrophy. These adaptations can enhance cardiac function (e.g. LV 
diastolic filling) in the resting condition and help meet the increased cardiac demands during 
exercise [28]. On the other hand, pathologic cardiac hypertrophy is characterized by 
predominantly increased LV wall thickness with unchanged LV chamber size, which is known 
to be a precursor of heart failure [22,23]. Moreover, the athlete’s heart does not result in 
dysfunction or heart failure, but is rather associated with sustained or improved contractile 
function. Since both athlete’s heart and pathologic hypertrophy associate with cardiac growth, 
there may be similarities in the molecular mechanisms underlying pathologic LV hypertrophy 
and exercise training-induced physiological LV hypertrophy [29]. However, research on the 
molecular mechanism behind athlete’s heart has so far been limited, but it is believed that the 
number and extent of such studies will increase in the near future, and the results may be 
important in understanding the differences in pathologic and physiological hypertrophy that 
can be important in treatment of heart disease. 
 
1.1.5 Molecular mechanism in heart failure 
The understanding of cardiovascular disease has evolved through the years by extensive 
studies emphasizing the identification of molecular and physiological mechanisms involved in 
normal and disease states. Major discoveries have been made along the way, e.g. it has long 
been known that HF is characterized by activation of the renin-angiotensin-aldosterone system 
(RAAS), catecholamine secretion and elevated cytokines in blood. This neuronal endocrine 
activation leads to progressive fluid retention as well as to increased peripheral vascular 
resistance. Most of the current standard treatment for HF (beta blockers and inhibitors of 
RAAS or of ANG II receptors) is based on this paradigm [30]. However, the majority of the 
work to find and explore the molecular mechanisms of HF has focused on specific genes or 
pathways rather than integrative approaches. 
The microarray technology dramatically accelerated the speed of discoveries by giving us the 
ability to simultaneously study thousands of genes in a single experiment. Novel molecular 
mechanisms have been identified, known pathways are seen under new light, disease 
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subgroups begin to emerge, and the effects of various drugs are molecularly dissected. Many 
of the proteins of hypertrophied cardiac myocytes show quantitative alterations that are 
proportional to the increase in size of the cell. This is a result of an increase in translation 
efficiency [31]. In addition, a significant number of the ~10 000 genes expressed in cardiac 
myocytes are either newly expressed or show changes out of proportion with the degree of 
hypertrophy [32]. These expressed genes, related to multiple biological processes and 
pathways are responsible for transducing mechanical and hormonal stimuli in the process of 
HF. However, common for many of the microarray studies of HF, e.g. those reviewed by 
Kittelson et al. [33], is that a significant amount of the regulated genes mainly belong to 
functional categories of cell growth and maintenance, cytoskeleton/sarcomere, metabolism 
and signal transduction, which correlates with what we found in Study II and IV. 
 
1.1.5.1 Metabolism 
The metabolism of the failing heart is altered. Under normal circumstances, fatty acids are the 
principal energy source of the heart, but in pathological hypertrophy, metabolism is switched 
to glucose utilization [34]. This can also be clearly seen from the results of our Study IV. 
Acetyl-CoA derived from FA and glucose oxidation is further oxidized in the tricarboxylic 
acid cycle (TCA) to generate NADH and FADH2, which enter the electron transport/oxidative 
phosphorylation pathway and drive ATP synthesis. Genes encoding enzymes involved at 
multiple steps of these metabolic pathways (i.e. uptake, esterification, mitochondrial transport, 
and oxidation) are regulated by the Peroxisome proliferator-activated receptor gamma 
(PPARγ) coactivator-1 (PGC-1α) with its nuclear receptor partners, including Peroxisome 
proliferator-activated receptors (PPARs) and Estrogen-related receptors (ERRs). It has been 
shown that PPARs also function as nuclear receptors for lipids and other metabolic substrates, 
and that they play a prominent role in this process [35]. Glucose uptake/oxidation and electron 
transport/oxidation phosphorylation pathways are also regulated by PGC-1α via other 
transcription factors, such as MEF-2 and NRF-1. It is therefore hypothesized that one of the 
key mechanisms in the energy substrate switch, in the hypertrophied failing heart, involves 
deactivation of the PGC-1α/PPARα complex at both transcriptional and posttranscriptional 
levels [36]. Changes in gene expression in the failing hearts include down-regulation of 
mitochondrial fatty acid oxidation and glucose metabolism enzymes and together this is 
consistent with observed metabolic alterations [37], as also detected in Study II and IV. 
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1.1.5.2 Structure/contractile proteins 
In HF several contractile proteins (e.g. Myosin, Actin, Tropomyosin, Troponins and Titin) are 
impacted by transcriptional changes, and this causes a change in the composition of the 
myosin subunit. It is known that in hemodynamic overload in rodents, there is a shift from the 
α-myosin heavy chain (α-MHC) towards β-MHC. This switch leads to altered cross-bridge 
cycling kinetics, resulting in an increase in the economy of muscle contraction [38]. The 
importance of accurate expression of contractile proteins, and their exact alignment in 
sarcomeres, is underlined by the fact that mutations in sarcomeric proteins and e.g. Titin can 
cause cardiomyopathy [39-41]. It is also well known that the cytoskeleton is important in 
cardiac hypertrophy and HF. It is believed that accumulation of Tubulin, Desmin and several 
other membrane-associated proteins are compensatory mechanisms typical of HF, independent 
of the underlying cardiac disease [42]. Such increase in cytoskeletal proteins accompanied by 
a loss of contractile filaments and sarcomeric skeleton components may be regarded as the 
morphological basis of contractile and diastolic dysfunction in the failing heart. 
In reaction to myocardial hypertrophy, an intricate series of changes in cellular and 
extracellular components are altered by changes in the extracellular matrix (ECM). The 
cardiac ECM is composed of 1) structural proteins, such as Collagen and Elastin; 2) adhesive 
proteins such as Laminin and Fibronectin; 3) anti-adhesive proteins such as Tenascin, 
Thrombospondin and Osteopontin, and 4) Proteoglycans [43]. Collagen and adhesive proteins 
bind to the cellular membrane through transmembrane receptors, such as the integrins. The 
interaction between adhesion proteins and cell membrane receptors ensure communication 
between the extracellular and intracellular environments [44]. Proteoglycans contribute to the 
architecture of the ECM, bind growth factors that participate in the paracrine cell to cell cross-
talk, and promote tissue remodeling and cell migration [45]. Normally, ECM synthesis and 
degradation are tightly regulated, but during myocardial remodeling, ECM synthesis increases 
and/or degradation decreases to yield an increase in ECM, leading to fibrosis. 
Matrix metalloproteinases (MMPs) are Ca2+- dependent endopeptidases that maintain 
homeostasis of cardiac structure by digesting the ECM. The MMP family consists of more 
than 20 proteins and they have different substrates, which include collagenases (such as MMP-
1 and MMP-13), gelatinases (MMP-2 and MMP-9), Stromelysin (MMP-3) and membranous 
type MMP (such as MT1-MMP). Most MMPs are inactive, secreted enzymes that act 
extracellularly after activation. However, the MMPS are regulated by a class of proteins called 
tissue inhibitors of metalloproteinases (TIMPs) and dysregulation of MMPs and TIMPs is 
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associated with various cardiovascular diseases and has been shown to be involved in 
hypertension and HF [46]. 
Increasing evidence suggests that binding of growth factors to the ECM is a major mechanism 
regulating growth factor activity. The ECM provides the architecture for multicellularity, 
whereas growth factors link ECM structures and molecules to the regulation of cell 
proliferation and differentiation. Growth factor signaling is not only genetically regulated 
inside the cell, but can also be modulated outside of cells by ECM proteins and enzymes. 
 
1.1.5.3 Cell growth and maintenance 
At the cellular level, pathological hypertrophy is accompanied by an increase in 
cardiomyocyte size, enhanced protein synthesis, reduced organization of sarcomeres, and re-
induction of a fetal cardiac gene program that ultimately weakens cardiac performance. 
Numerous extracellular agonists and, in particular, those that act through G-protein-coupled 
receptors, such as α- and β-adrenergic agonists, endothelin, angiotensin, and 5-
hydroxytryptamine, promote cardiac hypertrophy [47]. In addition, the complex molecular 
processes that lead to cardiomyocyte growth involve membrane receptors, second messengers, 
and transcription factors. The common final pathway of all these intracellular substances is 
gene expression, whose variations are now being revealed in increasing detail. 
Currently, growth promoting factors such as Angiotensin (Ang-II), Endothelin (ET-1), 
members of the Interleukin-6 (IL-6) family of proteins, Insulin-like growth factor-1 (IGF-1), 
Nitric oxide (NO) and others have been identified as direct triggers of a hypertrophic response 
at the level of the cardiomyocyte [47]. Atrial natriuretic peptide (ANP) and Brain natriuretic 
peptide (BNP) oppose the hemodynamic actions of the renin-angiotensin-aldosterone system 
(RAAS) by enhancing renal electrolyte and water excretion. Normally expression of these 
peptides is up-regulated in cardiac ventricles in response to pathological hypertrophy. 
Circulating levels of both ANP and BNP positively correlate with ventricular dysfunction, 
with plasma levels of BNP better reflecting the severity of heart failure [48]. Both ANP and 
BNP also oppose the hypertrophic effect of Ang II and Aldosterone on cardiomyocytes via the 
Guanylyl cyclase-A (GC-A) receptor and Cyclic guanosine monophosphate (cGMP) 
generation [49]. 
The cardiac interstitium constitutes a reservoir of growth factors, locally synthesized and 
released by different cell types in the myocardium, under the effect of mechanical, hormonal 
and electrical stimulation. Growth hormone (GH) and growth factors like IGF-1 also play a 
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role in the development, growth and function of the cardiovascular system. It is believed that 
GH and IGF-1 activate several mechanisms that protect against the development of heart 
failure in the short term. On the other hand, a condition of GH excess can cause cardiac 
dysfunction, but these functions are not yet completely understood [50]. In addition, it is 
known that among growth factors, the Fibroblast growth factor (FGF) family, including FGF-1 
and FGF-2, the Epidermal growth factor (EGF), the Vascular endothelial growth factor 
(VEGF), and IGF-1 are involved in hypertrophic effects of cardiac myocytes via autocrine and 
paracrine mechanisms. It is also known that other growth factors, such as Transforming 
growth factor β (TGF-β) and Platelet-derived growth factor (PDGF), modulate cardiac 
myocyte hypertrophy [51]. 
 
1.1.5.4 Cell signaling/communication 
Recent evidence suggests that normal (and exercise-induced) cardiac growth is regulated in 
large part by the growth hormone/IGF axis via signaling through the Phosphoinositide 3-
kinases (PI3K/Akt) pathway. In contrast, pathological or reactive cardiac growth is triggered 
by autocrine and paracrine neurohormonal factors released during biomechanical stress that 
signals through the Gq/phospholipase C pathway, leading to an increase in cytosolic calcium, 
activation of Protein kinase C (PKC), induction of immediate-early genes, re-expression of 
embryonic genes, and increased synthesis of contractile proteins [52]. In addition, a complex 
web of signaling pathways has been implicated in the transmission of stress signals leading to 
cardiac hypertrophy. Our Study II indicates differences in relation to these pathways in CAD 
and DCM. 
 
1.1.5.4.1 Kinase signaling 
Cardiac eutrophy and physiological hypertrophy are largely mediated by signaling through the 
peptide growth factors IGF-1 and GH. GH acts predominantly via increased production of 
IGF-1 [53]. When IGF-1, insulin, and other growth factors bind to their membrane tyrosine 
kinase receptors, the PI3K subgroup Iα is activated and phosphorylates membrane 
phospholipid phosphatidylinositol 4,5 bisphosphate [54]. This leads to recruitment of the 
protein kinase Akt (also known as protein kinase b) and its activator, 3-phosphoinositide-
dependent protein kinase-1 (PDK-1), to the cell membrane via interactions between kinase 
pleckstrin homology domains and the 3′-phosphorylated lipid [55]. Accumulated data suggest 
that PI3K/Akt signaling transduces adaptive cardiac hypertrophy; e.g., a central role of the 
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p110α pathway in IGF-1 induced growth and normal and exercise-induced hypertrophy was 
demonstrated utilizing mice expressing constitutively active or dominant-negative mutants of 
PI3K specifically in the heart [56]. Strikingly, the adaptive hypertrophy seen with constitutive 
activation of cardiomyocyte PI3K does not progress into a maladaptive hypertrophy. Further, 
supporting a critical role for the PI3K/PDK1/Akt pathway in regulating normal heart growth is 
the finding that cardiac-specific inactivation of PDK1 leads to reduced cardiac growth and a 
cardiomyopathic outcome [57]. Finally, cardiac-specific inactivation of Phosphatase and 
tensin homolog on chromosome 10 (PTEN), a tumor-suppressor phosphatase that negatively 
regulates the PI3K/Akt pathway by dephosphorylating 3′-phosphorylated phosphoinositides, 
resulted in cardiac hypertrophy [58,59]. 
As noted above, a major kinase effector of PI3K signal is Akt, which is at a signaling cascade 
branch point. While its effects on cell death/survival are directly mediated via phosphorylation 
of the Forkhead box, sub-group O (FOXO) family of transcription factors and other regulators 
of apoptosis [55], it is the two signaling branches downstream of Akt, not Akt itself, that 
largely determine the nature of a given hypertrophic response. One branch leads to 
mammalian target of Rapamycin (mTOR) and the protein synthetic machinery, which is 
essential for all forms of hypertrophy [60]. The other branch leads to Glycogen synthase 
kinase-3 (GSK-3), which also regulates the general protein translational machinery as well as 
specific transcription factor targets implicated in both normal and pathologic cardiac growth 
[61]. In addition, activity of both of these branches can also be regulated by stress activated, 
Gq-dependent mechanism that are independent of Akt. 
The heterotrimeric G-proteins Gq and G11 are functionally redundant transducers of 
phospholipase C signaling from prohypertrophic heptahelical receptors for angiotensin, 
endothelin, norepinephrine, and other neurohormones [62]. PKC- and inositol 1,4,5-
triphosphate (IP3) mediated calcium release are considered to be the major effectors of Gq 
signaling. However, PI3K-dependent signaling is also activated by this pathway but differs 
from physiological PI3K signaling in that the activated PI3K isoform (γ) is distinct from that 
activated by IGF-1. The mechanisms of its activation also differ, whereas p110α is activated 
via tyrosine phosphorylation by ligand-occupied growth factor receptors, p110γ is activated by 
recruitment to the sarcolemma by βγ subunits of activated Gq/G11, providing access to 
membrane phosphoinositides [54,62]. Strikingly, while p110α is required for normal or 
exercise-induced growth, but not pathologic stress-induced growth [63], p110γ is required for 
stress-induced hypertrophy, but not for normal growth [58,64]. Thus, PI3K signaling, 
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including that of Akt and both arms of its downstream signaling pathways (mTOR and GSK-
3), is activated in response to both physiological and pathologic stimuli, and either branch 
downstream of Akt can regulate adaptive and maladaptive growth. 
 
1.1.5.4.2 Calcium cycling 
It is well known that HF is characterized by a down-regulation in gene expression and activity 
of the Sarcoplasmic reticulum calcium ATPase (SERCA) [65]. Mutations in Phospholamban 
(PLN), an inhibitor of SERCA, can cause dilated cardiomyopathy in humans, by preventing 
Phospolamban phosphorylation, leading to constitutive SERCA2a inhibition [66]. In addition, 
alterations in the phosphorylation status of Sarcoplasmic reticulum (SR) calcium release 
channel (Ryanodine receptor (RyR)) are observed in failing hearts [67]. Together, these 
findings support the hypothesis that abnormalities in calcium handling play an important role 
in development of HF. The main events of calcium cycling in myocytes are illustrated in 
Figure 1. 
The sodium-calcium exchanger (NCX), which extrudes calcium from the cytosol in diastole, is 
up-regulated in HF, and is thought to be a counter regulatory process to reduction in SERCA 
[68]. In addition, the Plasma membrane calcium ATPase (PMCA), which transports calcium 
out of the cell, has been related to hypertrophy response. It is believed that in humans, SERCA 
accounts for approximately 70% of Ca2+ removal from the cytosol, NCX is responsible for 
28% and PCMA and mitochondria remove just 1-2% of cytosolic Ca2+. Its major functions are 
in the regulation of nitric oxide (NO) production in the myocardium and in leading signal 
transduction through the caveolae (structures in the cell membrane that carry a variety of 
receptors) [69]. 
The result of all these changes in Ca2+ related proteins is a reduction in peak systolic calcium, 
and an elevation and prolongation in diastolic calcium, resulting in reduced systolic 
contraction and a delay in diastolic relaxation, as well as impaired coupling of the calcium 
release. 
 
 - 19 -
 
Fig. 1. Role of Ca2+ ions in regulation of cardiac excitation-contraction. 
Reprinted by permission from Macmillan Publishers Ltd: Bers DM: Cardiac excitation-
contraction coupling. Nature 2002, 415: 198-205. [70], copyright 2002. 
 
1.1.5.4.3 Ion transporters 
In addition to changes in Ca2+ handling mechanisms, electrophysiological remodeling in HF is 
characterized by major changes in ion channel function and expression of several ion 
channels, pumps and exchanger proteins, which alter the electrical phenotype and predispose 
to the development of lethal HF. For example, it is well-known that cardiac Na+/H+-exchanger 
(NHE) activity is up-regulated in several in vivo and in vitro models of cardiac pathological 
hypertrophy [71,72]. Elevated NHE activity depletes the transmembrane Na+ gradient, which 
leads to increased intracellular Ca2+ mediated by the NXC (reviewed by Cingolani et al. [73]) 
and consequent activation of several signaling cascades (reviewed in Frey et al. [47]). 
Accordingly, inhibition of NHE by its specific inhibitor cariporide has been demonstrated in 
several studies [72,74-76] to "rescue" several models of cardiac hypertrophy in vivo. Because 
NHE inhibition does not appear to be associated with adverse hemodynamic consequences, 
this approach is a potentially interesting anti-hypertrophic treatment option. Several other ion 
transporting mechanism have also been suggested to be potentially novel targets in e.g. anti-
arrhythmic therapy [77]. 
 
1.1.6 pH regulation in cardiomyocytes 
It has been known for long that intracellular pH affects physiological processes profoundly 
(e.g. the contractile function), and a close control of hydrogen transport is therefore important. 
In cardiac myocytes several mechanisms maintain intracellular pH within a narrow range and 
 - 20 -
intracellular pH in myocardial cells is governed by the balance among four main sarcolemmal 
acid-equivalent ion transporters. The Na+/H+ exchanger (NHE) and the Na+/HCO3- (NBC) co-
transporter act to increase intracellular pH in acidosis [78-80] and the Na+-independent Cl-
/HCO3- exchanger (anion-exchanger, AE) and Cl--OH- exchange (CHE) reduce pH in alkalosis 
[81]. The NBC cotransporter seems to play the main role in regulation of intracellular pH 
close to normal range (7.05-7.24), whereas at more acidic conditions, the NHE is the main 
proton extruding mechanism. All these pH regulating mechanisms are known to be under 
hormonal regulation [82] and it is important to note that most neurohormones that induce a 
positive inotropic effect in the heart, in some way also affect the pH regulation system. In 
addition to the four main transporters, a third proton-extruding mechanism has been identified 
in rabbit cardiomyocytes, as a vacuolar proton ATPase (VPATPase), which is activated during 
acidosis [83]. The VPATPase probably acts to attenuate the reduction in intracellular pH in 
cardiomyocytes exposed to metabolic inhibition. It is also believed that other mechanisms are 
able to compensate for increased H+ load [83]. For example, lactate traverses the myocyte 
plasma membranes via a facilitated monocarboxylate transporter (MTC) system that functions 
as a proton symport [84] and Johannson et al. [85] showed that monocarboxylate transporter 1 
(MCT1) protein level was up-regulated in cardiomyocytes from chronic heart failure rats, 
which indicates that this system may help protecting the myocytes from acidosis. In Study I, 
we showed that H+/K+-adenosine triphosphatase (H+/K+-ATPase or proton pump) was 
expressed and regulated in rat cardiac myocytes, both at the transcript and protein level. 
Functional in vitro studies indicated that the H+/K+-ATPase may account for up to 25% of the 
K+-uptake in the ventricular cardiomyocytes. These findings indicate that the H+/K+-ATPase 
may share a pHi regulating role with the NHE1. In contrast, a recent publication by Kemi et al. 
[86] concludes that H+/K+-ATPase does not contribute significantly to pHi maintenance. 
However, the complete role of the H+/K+-ATPase in pH-regulation and/or cell volume 
regulation has not yet been determined. 
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1.2 Functional genomics 
Functional genomics is a field of molecular biology that attempts to make use of the wealth of 
data produced by genomic projects (such as genome sequencing projects) to describe gene 
(and protein) functions and interactions. Unlike genomics and proteomics, functional 
genomics focuses on the dynamic aspects such as gene transcription, translation, and protein-
protein interactions, as opposed to the static aspects of the genomic information such as DNA 
sequence or structure. Functional genomics uses high-throughput techniques mostly to 
characterize the abundance of gene products such as messenger ribonucleic acid (mRNA). 
Because of the large quantity of data produced by these techniques and the need to identify 
biologically meaningful patterns, bioinformatics is crucial to this type of analysis. 
 
1.2.1 From a single gene approach to genome wide gene expression analysis 
The sequencing of the entire human genome [87,88] has opened a new era in biomedical 
research in which gene identification and cloning is not pursued in the same scale as 
previously. The challenge is now to identify the function of the products of the genes in vivo, 
the diseases in which each gene is involved, and the therapeutic benefits to be gained from this 
information. Already, the use of gene expression analyses and gene array technology, together 
with advancements in proteomics, are beginning to be used to analyze e.g. genetically 
modified mice to determine “upstream” and “downstream” factors involved in the function 
and mechanism of action of a particular gene product. This is an important step towards the 
discovery of new diagnostic tools or novel drugs for the treatment of disease [89]. 
Microarray technologies have developed rapidly during the last decade and have changed the 
face of science. Today, microarray technology can be used for screening thousands of 
transcripts or single nucleotide polymorphisms (SNPs) or copy number variation or proteins or 
other biological components [90] in one single experiment. By conventional methods, this 
type of analysis would have taken several years. 
 
1.2.2 Microarray technology 
The history of microarrays begins more than 25 years ago with the Southern blot, which 
introduced the basic technique of anchoring nucleic acids to a solid support for analysis by 
hybridization [91]. Modern microarray analysis was for the first time introduced in 1995 by a 
Stanford research team led by Pat Brown and Ron Davis [92]. The authors described the use 
of a robotic system to spot deoxyribonucleic acid (DNA) oligonuclotides onto a glass slide in 
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ordered arrays, generating microarray slides. Only 45 oligonucleotide sequences were spotted 
on this first microarray, but the work initiated many new experiments and soon whole 
genomes of species such as yeast, bacteria, mice and humans were being spotted onto glass 
slides. In the same period of time when Brown et al. made the first microarrays at Stanford, 
Fodor et al. [93,94] invented a method for manufacturing microarrays by using 
photolithography for in situ synthesis of DNA probes on a silica wafer (commercialized by 
Affymetix Inc. (Santa Clara, CA)). This method was based on the principle that a set of 
oligonucleotide DNA probes (each approximately 25 nucleotides in length) is defined, based 
on its ability to hybridize to complementary sequences in target genomic loci or genes of 
interest. 
 
1.2.2.1 DNA microarrays 
A DNA microarray is a glass slide with attached DNA probes representing many genes 
arranged in a regular pattern. There are two major forms of DNA microarray technology: 
I. Complementary DNA (cDNA) arrays, where the probes are PCR products (200 ~ 2 000 base 
pair long) obtained from cloned cDNA libraries, printed by a robot, and immobilized on e.g. 
an aminosilane coated slide. Microarrays made from PCR-amplified cDNA clones are highly 
specific and produce strong signals because of the extended length of the cDNA. However, 
where sequence information is available, as in now often the case for most organisms, long 
oligonucleotides offer similarly strong signals and good specificity. Oligonucleotide arrays are 
now therefore replacing cDNA arrays for RNA based expression analysis. Each cDNA array is 
usually hybridized with two samples (two-color system), including an experimental and a 
control/reference sample. 
II. Oligonucleotide arrays, consists of oligonucleotide (20 ~ 80 mer oligos) probes that are 
synthesized either in situ (on chip) or by conventional synthesis, followed by immobilization 
on the array surface. This method, “historically” called DNA chip, was developed by 
Affymetrix, Inc. [93,94], but today there is a large variety of different oligonuclotide array 
formats. Each oligonucleotide array can be used with either two samples (two-color system) or 
only one sample (one-color system) (Figure 2.). 
The original DNA microarrays were used exclusively for expression analysis, but today 
oligonucleotide arrays are also used to identify sequence variations like SNPs, for genotyping 
and to resequence gene products [95]. 
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Figure 2. Overview of DNA Microarray Analysis. 
Panel A: In a two-color analysis, RNA samples from e.g. patients and control subjects are 
individually labeled with distinguishable fluorescent dyes and hybridized to a single DNA 
microarray consisting of individual gene specific probes. Relative levels of gene expression in 
the two samples are estimated by measuring the fluorescence intensity for each probe, a sample 
expression vector summarizes the level of expression of each gene in the sample obtained from a 
patient. Panel B: A single color analysis, performed with the use of Affymetrix GeneChip. 
Labeled RNA from each biological sample is hybridized to a single array in which a series of 
gene-specific probes are arrayed. Gene-expression levels are estimated by measuring the 
hybridization intensity for a series of “perfect match” probes, and the background is measured 
with the use of a corresponding set of “mismatch” probes. Gene-expression levels are reported 
for each sample as a sample expression vector that summarizes the difference between the signal 
and background for each gene. 
Reprinted by permission from Massachusetts Medical Society: Quackenbush J: Microarray 
analysis and tumor classification. N Engl J Med 2006, 354: 2463-2472. [96] (Copyright © 200x 
2006). 
 
1.2.2.2 Experimental design for DNA microarray experiments 
Good experimental design in a microarray project requires the same principles and practices 
that are part of any scientific investigation. Appropriate controls are the foundation to any 
experiment. Forethought and consultation on the correct statistical practices and procedures 
for the design are always advantageous. 
Optimizing design based on the experimental goal is an important part of a successful 
microarray experiment. One question that may be asked before designing an experiment is 
how much statistical power you wish to have to detect differentially expressed genes. This will 
determine the number of replicates needed [97]. Another question is what are the most 
 - 24 -
important samples, or comparisons you want to make, and how many experimental factors 
will be involved. For single-channel array experiments, it is obvious that more replicates 
should be done for samples of greater importance. For two-color array experiments, the many 
possible choices for designs pose a more complex problem which will be discussed in the 
following. 
 
1.2.2.2.1 Replication 
Replication is necessary in order to apply a statistical test and reduce variability inherent in 
microarray experiments. Replication falls into two categories; biological replicates and 
technical replicates [98]. In order to achieve results with any statistical confidence it is 
suggested that at least 3 biological replicates are used. Depending on the degree of intrinsic 
biological variation in the system, this may or may not be sufficient [99,100]. Technical 
replicates can be performed by using multiple arrays per sample. A second type of technical 
replication is dye-flip hybridizations (Figure 3.). A third type of technical replication is spot 
duplication on the slides where the conformity between the duplicate spot intensities can be 
used as a good indicator of the quality of the slides and the hybridization. However, biological 
replicates are more important than technical replicates [101]. So typically, a researcher should 
use biological replicates to validate generalization of conclusions and technical replicates to 
reduce the variability of these conclusions. 
 
1.2.2.2.2 Design alternatives 
The ability to make direct comparisons between two samples on the same microarray slide is a 
unique and powerful feature of the two-color microarray system. However, it is often 
impractical to make all possible pair-wise comparisons among the samples, because of cost or 
limitations in the amount of sample. Thus, an important step in designing an experiment is to 
decide how many technical replicates will be measured and how these will be paired together 
on arrays. The efficiency of comparisons between two samples is determined by the length 
and the number of paths connecting them [98,102]. It is most efficient to make the 
comparisons of greatest interest directly on the same array. Contrasts between samples that are 
never directly compared in an experiment are possible, provided that there is a path of 
comparisons linking them. 
A commonly used means of indirect comparison for microarray experiments is a reference 
design (Figure 3.). This design uses a common reference RNA. The intensity of hybridization 
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of a test RNA sample to a given spot is compared to the intensity of hybridization of the 
reference RNA to the same spot. An advantage of this method is that as long as the amount of 
reference sample is not limiting, the design can be extended to handle large numbers of 
samples, and in class discovery experiments samples from a new class can be added and 
analyzed at a later stage [103]. 
 
I 
 
 II 
 
Figure 3. Experimental design. 
Panel I. Experimental designs for the direct comparison of two samples. Boxes represent RNA samples 
that are labeled as varieties A or B. Subscripts indicate the number of independent biological replicates 
of the same treatment. Arrows represent hybridizations between the RNA samples and the microarray. 
The sample at the tail of the arrow is labeled with red (Cy5) dye, and the sample at the head of the arrow 
is labeled with green (Cy3) dye. The figures show a dye swap (a), a repeated dye swap (b), a replicated 
dye swap (c) and a simple loop design (d). 
Panel II. Experimental designs using a reference RNA sample. Boxes represent RNA samples, and 
arrows represent microarrays, as in panel I. Panel a: the standard reference design uses a single array to 
compare each test sample (A, B, C, and so on) to the reference RNA. Panel b: a variation, with a dye 
swap for each comparison. 
Reprinted by permission from Macmillan Publishers Ltd: Churchill GA: Fundamentals of experimental 
design for cDNA microarrays. Nat Genet 2002, 32 Suppl:490-5.: 490-495. [103], copyright 2002. 
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Other design alternatives may be loop designs (Figure 3.) or factorial designs. The simple loop 
design can be an efficient alternative to the reference design [98,104]. However, the estimation 
efficiency of a simple loop is greatly reduced by loss of just a single array [105]. The previous 
types of designs have been single factor experiments. Experiments investigating two or more 
factors require a more complex design [106]. A key premise is that it is possible to define an a 
priori number of contrasts that are of specific interest. The approach is then to design 
experiments that provide maximal information for these contrasts. 
 
1.2.2.3 RNA preparation, labeling and hybridization 
1.2.2.3.1 RNA quality 
The first and most critical step in sample preparation for DNA expression array analysis is 
isolation of total or mRNA from the experimental samples. The purified RNA should always 
be visualized by denaturating gel electrophoresis to verify the integrity of the ribosomal bands. 
This can be done by conventional gel electrophoresis [107] or by capillary electrophoresis e.g. 
with the Bioanalyzer (Agilent Inc. Palo Alto, CA) [108]. It is believed that the 18S to 28S ratio 
should be at least 1.8 and the RNA Integrity Number (RIN) [109] (obtained from the 
Bioanalyzer software) value above 7 to ensure good RNA quality [109]. In addition to gel-
electrophoresis it may be useful to measure the RNA integrity, quality and quantity by a 
spectrophotometer. The ratio absorbance at 260 and 280 nm is used to assess the purity of 
RNA. A ratio of ~2 is generally accepted as “pure” for RNA. The 260/230 ratio should 
commonly range from 1.8-2.2, and if the ratio is appreciably lower, this may indicate the 
presence of co-purified contaminants. If the RNA is degraded or contaminated, it will not be 
usable for labeling. For such analyses the NanoDrop (NanoDrop® Technologies Inc. 
Wilmington, De), a cuvette free spectrophotometer is useful. 
 
1.2.2.3.2 Labeling 
RNA extracted from biological samples is typically labeled with fluorescent dyes. The 
commercial cyanine dyes Cy3 and Cy5 are the most commonly used dyes in labeling reactions 
[110]. Fluorescence labeled samples can be prepared by several different methods including 
direct or indirect cDNA labeling [111-113] (Figure 4.). 
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Figure 4. Microarray target labeling procedures. 
The figures show a schematic representation of different experimental labeling procedures. Panel 
A: Direct labeling. Panel B: Aminoallyl indirect labeling. Panel C: Genisphere 3DNA labeling. 
Adapted and reprinted by permission from Molecular Vision: Yu J, Othman MI, Farjo R, 
Zareparsi S, MacNee SP, Yoshida S et al.: Evaluation and optimization of procedures for target 
labeling and hybridization of cDNA microarrays. Mol Vis 2002, 8:130-7.: 130-137. [111], 
copyright 2002. 
 
In the direct cDNA labeling method [114], fluorescence modified deoxynucleotides are 
incorporated during the first strand cDNA synthesis from an RNA template using reverse 
transcriptase. Although this method is relatively easy to perform, fluorescence modified 
nucleotides are bulky and Cy5- and Cy3-modified nucleotides may incorporate with different 
efficiency. In the indirect cDNA labeling method, e.g. aminoallyl-modified nucleotides are 
incorporated during reverse transcription reaction, and fluorescent dyes are subsequently 
coupled to the reactive amino groups in the cDNA. A different indirect method (3DNA by 
Genisphere Inc. Hatfield, PA) uses fluorescent dendrimer complexes to label cDNA [115]. 
After cDNA synthesis, a fluorescent dendrimer with hundreds of dye molecules per complex 
is hybridized to the cDNA. Affymetrix uses a different detection scheme than previously 
described, where mRNA is reverse transcribed into cDNA and then copied into biotinylated 
complementary RNA (cRNA) [116]. The biotin-streptavidin complex is then used to add the 
fluorescent tag. 
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1.2.2.3.3 Hybridization 
In a two color experiment, two labeled samples (unusually a “control” or a ”reference” sample 
and the sample of interest) prepared from two RNA sources are co-hybridized to the same 
DNA microarray (for some of the oligonucleotide array formats e.g. Affymetrix, only one 
sample is hybridized to each array). The conditions during this step must be optimized to 
promote specific binding of labeled samples to its target probes and to reduce background. 
Important parameters include hybridization temperature, length of hybridization, 
concentrations of salts, pH of the hybridization solution, and the presence or not of denaturants 
such as formaldehyde in the hybridization buffers [117]. During hybridization the arrays must 
be stored in a humidified, temperature controlled, dark environment. Small, affordable 
chambers that house one array work well, and can simply be placed in a standard incubator or 
water bath during the hybridization. However, today most users use automatic hybridization 
stations, where several arrays can be hybridized simultaneously and e.g. agitation can be 
applied to the samples during hybridization. Automatic hybridization stations have increased 
the quality of hybridization and post-hybridization wash and usually the specificity of the 
hybridization signal is increased and the background noise reduced. 
 
1.2.2.3.4 Scanning and image analysis 
After hybridization, arrays are typically scanned with an instrument that uses lasers as a source 
of excitation light and a photomultiplicator as detectors. This detection method allows 
determination of fluorescence from each of the labeled samples [118]. After scanning, image 
analysis must be performed to acquire target signal intensities [119]. Typically a program like 
GenePix (Axon Inc., Sunnyvale, CA) is used for image analysis of microarray data. Many 
image processing approaches have been developed [120-124], among which the main 
differences relate to procedures for spot segmentation (how to distinguish foreground from 
background intensities) [125,126]. Further analysis includes procedures like filtering, 
normalization and statistical analysis for finding differentially expressed genes or methods for 
clustering the genes or samples with similar expression patterns/profiles. 
 
1.2.2.4 Reporting microarray results 
Microarray studies generate large amounts of data which can not be published in journals. 
However, these data may be valuable to other researchers, so microarray data should be made 
publicly available. There are two main public repositories for microarray data: ArrayExpress 
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[127] at European Bioinformatics Institute (EBI) and Gene Expression Omnibus (GEO) [128] 
at National Center for Biotechnology Information (NCBI). These two and the proprietary 
repository Center for Information Biology gene Expression (CIBEX) [129] are recommended 
by the Microarray Gene Expression Data (MGED) society [130]. 
To compare data across experiments performed at different times and in different laboratories, 
all information related to the microarray experiments must be reported in a common way, 
using a widely accepted form. Such a form is called Minimum Information About Microarray 
Experiments (MIAME). The MIAME standard outlines the minimum information that should 
be reported about microarray experiment to enable its unambiguous interpretation and 
reproduction [131]. The MIAME includes a detailed description of the following six sections: 
experimental design, array design, samples, hybridization, measurements (raw expression 
data), controls [131]. Today most journals require microarray data to be MIAME compliant 
and that the raw data are submitted to a public repository [132,133]. 
 
1.2.3 Data collection and data analysis 
1.2.3.1 Data pre-processing and normalization 
Before it is possible to extract knowledge from microarray data, the raw data must be pre-
processed and normalized. The data extracted by image analysis must be pre-processed to 
exclude poor-quality spots and normalized to remove systematic errors before downstream 
analysis. 
Some commonly used methods for calculating normalization factor include: global 
normalization that uses all genes on the array, non-linear normalization method (lowess)[134] 
and internal controls normalization that uses known amounts of exogenous control genes 
added during hybridization [135-138]. In most cases the non-linear normalization method 
which corrects for dye basis of gene intensity and spatial information, is believed to be 
superior to the other methods. In addition, if there is a significant difference in the distribution 
of log-ratios among the print-tips, suggesting a possible spatial effect, print-tip group lowess 
normalization should be considered [137]. Apart from within a single array, the distribution of 
gene expression ratios from replicate experiments might have different distribution of log 
ratios. Therefore scaling adjustment may be necessary to standardize the distribution of log-
ratios across replicate experiments to prevent any particular experiment from becoming 
dominant and affecting downstream statistical analysis [135]. 
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For global and lowess normalization a comparable global gene expression is expected between 
the two samples. If there is a global shift between the samples these normalization methods 
will bias the results. In such cases normalization by internal controls (spikes) is a good 
solution [139-141]. External spike mRNAs may be added to the samples in predefined ratios 
and the normalization can be done by adjusting the observed ratios compared to the theoretical 
ratios [142-144]. 
 
1.2.3.2 Finding differentially expressed genes 
Fold change (FC) was the first method used to evaluate whether genes are differentially 
expressed, and is a reasonable measure of effect size. However, it is widely considered to be 
an inadequate test statistics because it does not incorporate variance and offers no associated 
level of confidence [145]. Another method of identifying differentially expressed genes it the 
use of a two-sample t-test (or one of its nonparametric equivalents, e.g., Mann-Whitney U test) 
to calculate p-values [146]. Basically, this step involves statistical hypothesis testing where a 
null hypothesis (the nonexistence of differential expression) is contrasted to an alternative 
hypothesis (the existence of a differential expression). The calculated p-value represents a 
threshold for which the null hypothesis is rejected (the alternative hypothesis is accepted), and 
therefore observed differences in gene expression are statistically significant. In addition, 
identifying genes that are differentially expressed across more than two samples can be 
achieved in a way similar to what was described above, but using different tests, for example, 
ANOVA (analysis of variance) or equivalent nonparametric tests such as Kruskal-Wallis 
analysis of ranks [146]. ANOVA is common tool for studying data from experiments with 
multiple categorical factors [147]. The ANOVA model accounts for multiple sources of 
variation in microarray experiments. Significance analysis of microarrays (SAM) [148] is 
another approach that has been used in many studies. SAM identifies genes with statistically 
significant changes in expression by identifying a set of gene-specific statistics (similar to the 
t-test, thus taking into account both magnitude of change and variability of expression) and a 
corresponding false discovery rate (similar to a P value adjusted for multiple comparisons). 
Several other methods based on e.g. regression modeling [149], the empirical Bayes method 
[150], and the mixture model [151] have also been used for finding differentially expressed 
genes from microarray experiments. 
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1.2.4 Knowledge discovery 
1.2.4.1 Learning 
Soon after microarrays were introduced, many researchers realized that learning techniques 
could be used to discover new subclasses in disease states [152,153], to identify biomarkers 
associated with disease and even that the expression patterns of the genes could be used to 
distinguish subclasses of disease [154-156]. 
Many different learning algorithms are today extensively used in microarray research. The 
different algorithms are used either to discover new categories within a data set (class 
discovery; unsupervised learning) or assign cases to a given category (class prediction; 
supervised learning/classification) [157]. 
 
 
Figure 5: Unsupervised versus supervised learning. In unsupervised learning multiple samples 
are clustered into groups based on overall similarity of their gene expression profiles. This 
approach is useful for discovering previously unappreciated relationships. In supervised learning 
multiple samples from different known classes are used to train a model capable of classifying 
unknown samples. This model is then applied to a test set for class label assignment. 
Reprinted by permission from the American Society of Clinical Oncology: Ramaswamy S, 
Golub TR: DNA microarrays in clinical oncology. J Clin Oncol 2002, 20: 1932-1941 [157], 
copyright 2002. 
 
1.2.4.1.1 Unsupervised learning 
Algorithms for unsupervised learning or cluster analysis group objects on the basis of some 
sort of similarity metric that is computed for one or more “features” or variables. For example, 
genes can be grouped into classes on the basis of the similarity in their expression profiles 
across tissues, cases or conditions. Hierarchical cluster analysis graphically presents results in 
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a tree diagram (dendrogram), and is probably the most common unsupervised learning 
algorithm in microarray analysis [158]. Its popularity is understandable because no hypotheses 
and almost no data assumptions are required, but the researcher is quite certain to obtain a 
clustering of samples or genes, irrespective of sample size, data quality or experimental design 
or indeed any biological validity that is associated with the clustering. 
Non-hierarchical clustering methods divide the cases (samples or genes) into a predetermined 
number of groups in a manner that maximizes a specific function (for example, the ratio of 
variability between and within clusters) [159]. 
 
1.2.4.1.2 Supervised learning 
In supervised learning (often called “classification”, “class assignment”, “class prediction” or 
“class discrimination”), the aim is to obtain a function or rule that uses expression data to 
predict whether a case is of one type or another (for example, drug-resistant versus non-drug-
resistant). For example, a rough set algorithm finds the rule that best classifies a set of 
available cases for which the correct type is known [160]. First the samples are divided into 
groups based on e.g. a clinically relevant parameter such as disease aetiology, prognosis, or 
response to therapy. Then a molecular signature is created by choosing genes whose 
expression is solidly associated with the parameter in question, by weighting genes based on 
their individual predictive strengths. 
Algorithms are typically developed on a “training” data set and evaluated on an independent 
“test” data set. The requirement for both the “training” and “test” data set is that the categories 
to which objects belong are known. Many supervised classification algorithms are available. 
The great challenge is to determine the optimal degree of model complexity that a given data 
set can support. A common misconception is that the set of the most differentially expressed 
genes will necessarily give the best predictive accuracy. The gene list that is obtained from 
hypothesis testing does not necessarily give the best prediction. No one method for 
constructing prediction algorithms is widely accepted as superior or optimal. However, 
experience suggests that with the sample sizes that are typically available in microarray 
studies, simpler methods might out-perform more complex approaches. 
 
1.2.4.2 Gene annotation 
A “gene annotation” is a “comment” attached to a gene or gene product, which can be a 
protein. The comments can, for example, be a DNA or peptide sequence, describe the 
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biological functions of the protein, its interactions with other genes/proteins, and the metabolic 
pathways in which the protein is active. In microarray experiments, after the genes of interest 
have been identified using statistical tools, their annotations should be acquired, in order to 
make inferences about the validity and biological interpretations of the findings, and to 
generate new hypotheses. 
 
1.2.4.2.1 Retrieving annotations from public databases 
The meta-analysis of microarray data sets largely depends on rapid access to previously 
described annotations of the genes being studied. Today, diverse publicly available resources 
exist that catalog various attributes of genes, ranging from their mapped coordinates within the 
genome to the enzymatic function of the proteins they encode. These include GenBank [161], 
UniGene [162], Entrez (LocusLink) [163], SwissProt [164], Online Mendelian Inheritance in 
Man (OMIM) [165], PubMed [162], as well as many others. Although these resources are 
highly informative individually, the collection of available content is of higher value when 
provided in a unified and indexed in a robust manner. Several web-based database tools like, 
SOURCE [166], GeneCards [167], GeneCruicer [168], NetAffx [169] and GeneTools [170] 
(Study III) are now available. These tools are designed to bring together annotation 
information from a broad range of resources, and provide it in a manner particularly useful for 
genome-scale analyses, which means that lists of gene reporters can be submitted and the user 
receives annotation information for all these in one query. 
 
1.2.4.2.2 Gene ontology 
The Gene Ontology (GO) project was founded to advance the development and utilization of 
bio-ontologies and semantic standards for molecular biology [171]. The GO is divided into 
three sub-ontologies: molecular function (MF), biological process (BP), and cellular 
component (CC), to describe attributes of gene products or gene product groups. Briefly, MF 
describes what a gene product does at the biochemical level. BP describes a broad biological 
objective. CC describes the location of a gene product, within cellular structures and within 
macromolecular complexes [171]. 
The GO ontologies are structured vocabularies in the form of directed acyclic graphs (DAGs) 
that represent a network in which each term may be a “child” of one or more than one 
“parent”. Relationships of child to parent can be of the “is a” type or the “part of” type. The 
“is a” type refers to when a child is an instance of the parent. For example, nuclear 
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chromosome “is a” chromosome. “Part of” is slightly more complex. For example, A “part of” 
B means that whenever A is present, it is always a part of B, but A does not always have to be 
present. An example can be nucleus “part of” cell. Nuclei are always part of a cell, but not all 
cells have nuclei. 
The annotations of gene products to the GO vocabularies are attributed to a source, which may 
be a literature reference, another database, or a computational analysis. The annotations 
include not only the source attribution, but also an indication of the evidence on which the 
annotation is based. A simple controlled vocabulary (evidence codes) is used to describe the 
evidence supporting the attribution, such as “traceable author statement” or “inferred from 
direct assay”. Referencing each annotation with both experimental method and citation is 
intended to help researchers evaluate the reliability of an annotation and is critically important 
to the future evaluation and use of these annotations [172]. The ontologies and annotations are 
provided publicly as part of the GO database resource (http://www.geneontology.org/). 
 
1.2.4.3 Gene-class testing 
Among the most widespread applications of GO data is the use of GO terms and gene product 
annotations to help interpret the results of microarray experiments. Correlation between the 
functional information captured by GO and the expression patterns of a set of genes (gene-
class testing) can help to highlight underlying biological phenomena. Comparisons of gene 
lists are important in order to answer questions such as “are genes involved in process P 
overrepresented among the total of differentially expressed genes in an experiment” or “does 
treatment A induce more genes involved in process P than treatment B?”. 
Several software tools have been developed to facilitate the analysis of gene expression data 
using GO (www.geneontology.org/GO.tools.microarray.shtml), and some papers reviewing 
the relative merits of a subset of these tools have recently been published [173-175]. These 
tools are suited for analysis of the GO hierarchy and for statistical evaluation of GO category 
representations between gene lists [176]. Several different statistical tests are offered through 
the different tools, and suit different situations/questions. 
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2. Objectives 
The main purpose of this project was to investigate molecular mechanisms of myocardial 
hypertrophy and heart failure in experimental models and clinical samples. We aimed to 
establish and use microarray technology and bioinformatics tools to obtain these results. 
 
The specific objectives of the studies were 
 
Study I 
To explore the presence and localization of H+/K+-ATPase gene and protein expression in the 
rat heart, and to investigate whether the enzyme could contribute to potassium transport across 
the sarcolemma. 
 
Study II 
To use gene expression profiling, gene-class testing methods built on functional annotations 
(GO) and supervised classification to identify aetiology-specific biological processes and 
potential molecular markers (classifiers) for different aetiologies of end-stage heart failure. 
 
Study III 
To develop a general gene annotation tool that could handle information from microarray 
studies. Important features should be user friendliness, recent updates of annotations, options 
to add user-defined annotations, and procedures for statistical hypothesis testing. 
 
Study IV 
To identify genes and gene-classes related to biological processes that are differentially 
regulated during hypertrophy development and genes whose expression differ between 
pathological and physiological hypertrophy. 
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3. Methodical considerations 
 
3.1 Animal models 
Due to limited availability of human cardiac tissue, we chose animal models for cellular and 
molecular analyses of heart failure and hypertrophy mechanisms in Studies I and IV. 
 
3.1.1 Rat myocardial infarction and heart failure model 
The rat was chosen because the species has been extensively studied in cardiovascular disease 
and many of the similarities and differences to human physiology and pathophysiology are 
known. Adult female Sprague-Dawley rats were used to minimize physiological growth 
throughout the study period. In Study I and IV, infarctions were induced by ligation of the left 
coronary artery. This method is well established in our laboratory [75,177,178]. 
To verify myocardial infarction and to assess the extent of heart failure, left ventricle (LV) 
pressure and infarct size were measured by echocardiography. The myocardial infarction 
model is an established heart failure (HF) model with high prevalence of severe HF dependent 
on infarct size [179-181]. It has many similarities to human post-infarction HF and the 
coronary artery ligation induces a transmural myocardial infarction in the free wall, with 
infarction size dependent on the ligature positioning. Within few days the infarct area is 
macroscopically demarcated to the non-infarcted tissue. LV remodeling occurs in the rat 
model similarly to the human, except that scar formation is complete earlier (3 weeks vs. 4-5 
weeks). After large myocardial infarctions, LV remodeling and cardiomyocyte hypertrophy is 
progressive and contractile function and calcium handling is impaired [182,183]. 
Dissimilarities between experimentally induced pathology and disease are usually marked. HF 
due to one large, well defined transmural infarction after permanent coronary artery ligation 
may differ significantly from clinical ischemic HF. Patients usually have diffuse CAD with 
recurrent infarctions and modern interventions frequently result in reperfusion of the infarcted 
area. 
In Study I, we used LV pressure measurements to detect differences in contractile functions 
between sham operated animals and infarcted rats. It has been established that the maximum 
rate of rise of left ventricular pressure, dP/dtmax, is a sensitive measurement of acute changes in 
LV contractile function. LV dP/dtmax also correlates with basal contractility in failing and non 
failing hearts but is affected by pre-load, heart rate and hypertrophy [184]. Interpretation of 
dP/dtmax must therefore be done with these limitations in mind. 
 - 38 -
 
3.1.2 Rat exercise training program 
To maximize cardiovascular adaptation and induce physiological hypertrophy in Study IV, we 
chose to use a custom made inclined treadmill running model, which allows us to have close 
control of exercise intensities and training adaptation. This model has been extensively 
characterized and used in our laboratory and described in detail by Wisloff et al. [185]. In this 
running model, the exercise sessions were carried out for 1.5 h/day, 5 days/week, in intervals 
of 8 min at 85-90% of maximal oxygen uptake (VO2max). To reduce the speed, uphill treadmill 
running was performed. This results in a full body exercise that taxes the cardiovascular 
system maximally, and mimics physiological adaptations in humans [186,187]. Several studies 
from our laboratory confirm that hypertrophy is induced after 4 weeks with this training 
program by increased LV and RV weights and myocyte length [185,187,188]. In contrast to 
pathologic hypertrophy, our model of exercise training-induced hypertrophy is associated with 
improved contractile function and calcium handling in the cardiac myocytes [187,188]. Due to 
these characteristics, this rat treadmill exercise program serves as a good model for 
physiological hypertrophy. 
 
3.2 Human samples 
In Study II, tissue samples from transplant and normal hearts were used. Compared to e.g. the 
rat myocardial infarction model, the human infarcted myocardium samples were much more 
inhomogeneous. Typically, more scar tissue was included in the samples. For the RNA 
isolation we tried to avoid these areas of the tissue samples as much as possible. Among other 
factors, differences in age and degree of failure introduce more variability in the data 
generated in this study than for the rat model. 
A second difference compared to the rat model is that the non-failing human subjects were 
significantly younger than the patients with failing hearts and most of the non-failing patients 
were females whereas the failing patients were males. However, this did not seem to influence 
the results and we were not able to connect the pattern of differentially expressed genes to 
gender. Despite this biological variation in the samples we were able to find expression 
patterns that were significantly different between failing and non-failing hearts, and between 
different aetiologies, such as CAD and DCM. 
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3.3 Gene expression measurements 
3.3.1 Competitive rt-PCR 
For the competitive reverse transcriptase polymerase chain reaction (rt-PCR), we cloned two 
PCR products; one from the rt-PCR and one from a PCR of genomic H+/K+-ATPase 
(competitor). These clones were purified, quantified and used as a standard curve and a 
competitor for each sample that were tested. In the rt-PCR reactions, we always included the 
“genomic” competitor and after gel electrophoresis the expression bands were related to the 
standard curve and corrected for the competitor. In this way we were able to assess RNA 
expression in a semi quantitative manner. This method did not allow us to measure the 
accurate number of transcripts expressed, but it was good enough to distinguish between 
different groups of samples compared. Several other studies in our group and elsewhere have 
used this method with success [75,177]. 
A limitation of this method is that we were not able to correct for different amounts of input 
RNA, but this could have been tested by using a “house keeping” gene as control. To 
compensate for this, we used several biological and technical replicates that give statistical 
power. In addition, we established a second assay for Nppa (ANF) expression where we, for 
these samples, confirmed known expression patterns. A second limitation of this competitive 
rt-PCR method is that a genomic competitor was used. By using an RNA competitor we would 
have been able to control every step from the cDNA synthesis and we think this would have 
increased the possibility to quantify the exact amount of expressed transcripts. However, this 
is not usually the main focus for researchers, who often need to have a method that can 
distinguish gene expression between groups of samples. 
 
3.3.2 Real time PCR 
In Study II we used real time PCR (RT-PCR) for verification of microarray results. RT-PCR is 
a more sensitive and easier method to perform, than competitive rt-PCR. 
Several algorithms have been developed to calculate absolute quantitative measurements, but 
how good these really are is still debatable. We chose to use TaqMan chemistry for the RT-
PCR reactions and for relative quantification we used a modified ∆∆CT equation [189]. For 
these assays we chose to use Beta-actin to normalize the RT-PCR expression ratios for each 
individual sample. What genes that can act as “house keeping” genes in a heart is not well 
known. Several studies have found that most genes commonly known as “house keeping” 
genes may be differentially expressed in different cardiovascular settings. We tested Beta-
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actin in heart failure samples vs. non-failing samples and in different aetiologies of heart 
failure, and did not find any significant differences in gene expression between the biological 
samples. Moreover, these analyses showed a close correlation with the microarray results for a 
sub-set of genes. 
Today, most reviewers of microarray manuscripts require RT-PCR verification of the 
microarray results. Several studies have been done and most of them conclude that microarray 
results and real time data correlate very well. Since these two methods measure gene 
expression at the same biological level, it has been concluded [101] that in some situations this 
type of verification is unnecessary. Functional verifications with enzymatic assays or protein 
measurements may therefore be more relevant. However, the reason that many reviewers still 
require verification is that in the early days of microarry technology, the gene probe quality 
was poor and the user could not be sure that he was looking at the gene he though the clone 
represented. This problem will be discussed in the next chapter. 
 
3.3.3 DNA microarray analysis 
3.3.3.1 cDNA microarrays 
Only cDNA microarrys were available when the studies of the present project were performed. 
We used glass microarrays with cDNA probes (200-2.000 nucleotides in length) printed by the 
Norwegian Microarray Consortium (NMC). The clones for the cDNA probes were purchased 
from the IMAGE consortium [190]. Errors in the IMAGE collections of clones have been 
reported, and additional errors may have occurred during production. As a response to this, 
NMC resequenced a large proportion of the printed PCR products from both the human and 
rat libraries. They found that ~70-80% of the human clones and ~60-70% of the rat clones 
could be verified. Among the remaining 20-40% of clones, not all are likely to be “wrong”. 
Some could be classified as “not verified” as a result of e.g. lack of successful sequence 
reactions. Uncertainty of the exact nature of probes is a general concern with cDNA 
microarrays and a strong argument for verification of microarray data with other methods. In 
Study II, we resequenced the most significant genes and all were found to be correct. In 
addition, we focused less on single genes, but more on functional groups (e.g. GO-classes) of 
genes that were differentially expressed between the studied groups. These strategies are well 
suited to increase reliability of our interpretations. 
A second concern when using cDNA microarrays is cross-hybridization of the labeled sample 
to non-target homologous probe sequences on the microarray [191,192]. This cross-
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hybridization is mainly due to hybridization between the poly(A)-tail of the sample mRNA 
and the cDNA probes which also contain poly dA/dT sequences. Different blocking solutions 
are used in order to prevent this unspecific cross-hybridization. We used standard oligo dT and 
cot-1 blocking. A new alternative is the LNA dT blocker from Genisphere. The potential 
problem with the use of dT blockers is that the concentration of PCR products on the array and 
between batches of arrays may vary. Therefore, it is difficult to find the optimal concentration 
of blocking reagents to use. However, methods for solving this have been developed (Bruland 
et al. paper submitted). 
At the time of our first microarray experiments, we did not have full knowledge of this 
potential problem and just standard amounts of blocking reagents were used. Moreover, the 
variable length of the PCR product printed on the microarrays makes it difficult to find an 
optimal hybridization and washing temperature. We think this is the main reason for the 
observation of compressed expression ratios, compared to e.g. RT-PCR experiments. 
Important issues are still the choice of microarray platform, labeling method and quality 
control, but it is now believed that most platforms individually work well (in good hands and 
with standardized protocols) and produce similar results (at least according to the 
representation of the function to the genes found), so local experience with the technology is 
essential [193-195]. However, there are still many problems to solve. Shields [196] has 
discussed some of those in a recent paper and suggest that it is time to go beyond MIAME to 
reach the desired level of confidence. What is needed is a proper evaluation of microarrays 
(including sample extraction and work-up, data handling and analysis) and an understanding 
of what is important to achieve consistent, accurate and reproducible results across 
laboratories. However, recently both US and European projects have been established to work 
with such issues. 
 
3.3.3.2 Labeling methods 
In the present studies (Study II and IV) we used a microarray labeling and hybridization 
protocol that enables the use of small amounts (1-5 µg) of RNA without amplification [115]. 
The 3DNA labeling system (Gensiphere INC.) provides a more predictable and consistent 
signal than direct labeling and than several of the other indirect labeling methods. There are 
two main reasons for this: First, the fluorescent dyes are a part of a 3DNA dendrimer, and it 
does not have to be incorporated during the sample cDNA synthesis. This avoids ineffective 
cDNA synthesis and unequal incorporation of the two dyes (e.g. Cy5 and Cy3), which can be 
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a problem in direct labeling methods. Second, because each 3DNA molecule contains the 
same number of fluorophores (approximately 350 for the Genisphere 350 3DNA kit), the 
signal generated from each sample cDNA molecule will be largely independent of base 
composition or length of the transcript. In contrast, the signal from direct and most indirect 
labeling methods will vary depending on the base composition and length of the sample cDNA 
generated during labeling. 
In our studies (Study II and IV) and in other early microarray studies using the 3DNA method, 
compressed ratios are observed. In addition to possible unspecific binding, this appears to be a 
result of low dynamic range of the fluorescence signals obtained. Studies comparing different 
labeling methods confirm this [112,197]. Despite these limitations, we and others 
[143,198,199] have shown that the 3DNA method can identify differentially expressed genes, 
since we have obtained good results using external spikes, and since the RT-PCR verification 
results fit well with the obtained microarray results. After our Study I was finished, the 3DNA 
protocols were improved and new equipment has been made available. Among the 
improvements of the protocols is the introduction of a “two-step” hybridization (used in the 
exercise part of Study IV), where the sample cDNA first is hybridized to the array and then the 
fluorescent dendrimers are hybridized to the target sequences in a second hybridization before 
wash and scanning. In addition, Gensisphere has introduced the LNA blocking solution 
(described in section 3.3.3.1) which works well on cDNA arrays. Today most laboratories 
have automatic hybridization stations that ensure good mixing of the cDNA, constant and 
precise temperature under the hybridization, and stringent and equal wash conditions. 
Together, these improvements result in better signal to noise ratios, and an increased dynamic 
range of the signals. 
 
3.3.3.3 Quality control 
There is a mounting call for standards and quality control (QC) of microarray experiments. In 
every step, from sample preparation to data analysis, there is QC that can be performed. 
However, still good systems are missing for assessment of technical quality of the microarray 
experiments. Two characteristics of performance are very important, accuracy and precision. 
The assessment of these factors can be either for the purpose of technology optimalization or 
for the evaluation of individual hybridizations. Whereas accuracy refers to how close a 
measurement is to the real value, precision indicates how often a measurement yields the same 
result. When microarrays are discussed, the focus is often on precision, which relates to 
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reproducibility rather than accuracy. This is due to the fact that reproducibility is relatively 
easy to assess by performing repeated measurements. However, as discussed below, several 
types of external controls can be used for accuracy assessments of microrray data. 
A very useful tool is external spike controls. Spike controls consist of exogenous RNA 
transcripts, which are added to the RNA samples prior to reverse transcription and labeling. 
For Study IV we used a commercial SpotReport Array Validation System (Stratagene, La 
Jolla, CA) to measure hybridization quality. To use this system, the arrays were spotted with 
probes for the exogenous transcripts. Different amounts of each exogenous transcript were 
added to the test and control sample to generate pre-defined ratios (10 different ratios) 
between the fluorescence signals for the two samples compared on a slide. In this way we 
were able to mimic differentially expressed genes. This information can be used to evaluate 
the reverse transcription, labeling and hybridization procedures, as well for assessing the 
dynamic range of the signal intensities. An extended spike set up can increase the value of 
using spikes as a QC method. An ideal set up may include 20-30 different spikes which are 
printed in all sub arrays. A wide distribution in the signal intensities (with log2 ratio 0, 
normalization controls), that covers the entire range of mRNA levels, will allow normalization 
using the spikes. This may be very important in analysis of microarray data if a global shift in 
gene expression is observed [200]. In addition, it is advantageous to include spikes at ratio 
levels that are both higher and lower than the range that is strictly required. So, in addition to 
include non-differential (normalization) controls, spikes designed to measure both low (two 
fold) and high (ten fold) differentials in a single experiment are useful. 
 
3.3.4 Learning 
Right from the beginning of microarray history, clustering and classification have been 
popular analysis methods. However, it is believed that unsupervised learning (class discovery) 
is overused. First, little information is available about the absolute validity or relative merits of 
clustering procedures [201,202]. Second, the evidence indicates that the clusters that are 
produced with typical sample sizes (<50) are generally not reproducible [203]. Third, and 
most importantly, unsupervised learning rarely seems to address the questions that are asked 
by biologists, who usually are interested in identifying differential expression. However, it is 
important to note that there might be cases where clustering is warranted, e.g., if the goal is to 
simply obtain a general description of how genes co-vary with respect to their gene expression 
levels within a population. 
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In supervised learning (class prediction), the aim is to obtain a function or rule that uses 
expression data to predict whether a case is of one type or another (for example, coronary 
artery disease vs. dilated cardiomyopathy as described in Study II). For example, a rough set 
algorithm finds the rule that best classifies a set of available cases for which the correct type is 
known. Because of this attempted optimization, over-fitting might be a concern. To estimate 
how well the rule will perform on fresh data, one should cross validate it on test data that are 
completely independent of the data from which the classification rule was derived, and there 
are many approaches to this [204]. One key point is the need to avoid selection bias. This 
requires cross-validation procedures that separate the validation data from all aspects of the 
rule derivation process, including the selection of initial transcripts to include in the model 
[205-207]. Early microarray papers failed to account for selection bias and thereby radically 
overestimated prediction accuracy. Effective cross validation requires an adequate sample 
size, and methods for estimating sample sizes for supervised learning studies have been 
developed [208-210]. 
A limitation of our study (Study II) where we used supervised learning to obtain classifiers 
that could distinguish between CAD and DCM samples was that the pool of samples was 
small (approximately 10 different individuals in each group), so it was not possible to use a 
subgroup of the samples as a test set for cross-validation. However, we used a “leave one out” 
algorithm for cross-validation to reduce overfitting. Future studies should ensure that a large 
population of samples is available, to facilitate the use of a stringent learning set/test set 
method. Admittedly, for some diseases and probably especially for cardiovascular research 
and diagnostics, this may be difficult to obtain. Possibly, in some cases, animal models can be 
used to explore molecular patterns that could classify different cardiovascular diseases or 
states of disease. 
 
3.4 Gene annotation 
3.4.1 Annotation databases 
Microarray analysis generates lists of gene reporters that need to be connected to annotation 
data. To perform this individually for each gene is very time-consuming. Therefore, tools that 
allow batch searches have increased the usability of such tools. Tools for meta-analysis may 
be more useful and powerful if more types of data are integrated in a coherent way. Further, a 
dedicated annotation database that integrates various types of data from various sources is 
potentially better than any single database. However, not many such tools are available. The 
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main problems in building such an integrated database is difficulties in design and the need to 
update every time any one of its source databases is updated. This places a heavy burden on 
the team maintaining it. Given this, it is understandable that most tools available today use 
only one of the available annotation databases. In the future, at least in the context of the 
development of systems biology, databases that offer information from several sources will be 
essential. 
However, there are still limitations even with the current annotation databases. First, the 
existing databases are incomplete. For virtually all sequenced organisms, only subsets of 
known genes are functionally annotated. Furthermore, most annotation databases are built by 
curators who manually review the existing literature. It is therefore possible that certain known 
facts might get temporarily overlooked. However, even more commonly, recent annotations 
are not in the databases yet because of the time lag necessary for the manual curation process. 
In this context we hope that our GO Annotation Tool [170](part of GeneTools, study III) can 
be a valuable tool. Until today most of the annotations have been performed by small groups 
of scientists, but now “regular” users can add annotations to their genes and choose to share 
these with the scientific community (export to GOA [211]). Hopefully, this can contribute to 
increasing the number of annotated genes and to speed up the annotation process. 
A second problem with the annotation databases today is how genes are “named”. Each 
resource often uses its own type of identifiers. For instance, GenBank uses accession numbers, 
UniGene uses cluster identifiers etc. Furthermore, genes are also represented by various 
company specific gene IDs. Various resources try to address this problem by maintaining 
different types of IDs together. For instance, beside its own gene names, EntrezGene database 
[163] also contains UniGene cluster IDs, and Affymetrix's NetAffx [169] provides RefSeq and 
GenBank accession numbers, beside its own array specific probe IDs. The burden of mapping 
various types of IDs to each other is left entirely to the researchers, who often have to revert to 
cutting and pasting lists of IDs from one database to another. The name space issue 
(connection between a specific sequence e.g. a probe and a gene) becomes crucial when trying 
to translate from lists of differentially expressed genes to functional profiles because the 
mapping from one type of identifier to another is not one to one. Consequently, the type of IDs 
used to specify the list of differentially regulated genes can potentially affect the results of the 
analysis [176,212], so the name space problem has yet to be solved. However, we recommend 
using primary IDs like e.g. GenBank accession numbers to decrease this problem. 
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Today, GeneTools is one of the largest sources that offer gene/protein annotations from 
several database sources. However, more annotations, through import of additional external 
databases should be added. A potential expansion may be to include information from 
Ensembl (genome browser) [213], the HapMap Project [214] and Kyoto Encyclopedia of 
Genes and Genomes (KEGG) [215]. To facilitate utilization of systems biology approaches, it 
would be advantageous if gene expression data were available. Finally, to ensure a good 
accessibility, the export formats can be extended e.g. by offering export in SBML (the systems 
biology markup language) [216] format. 
 
3.4.2 Gene ontology 
As mentioned earlier, the meta-analysis of microarray datasets largely depends on rapid access 
to previously described features/annotations of the genes being studied. Today, various 
publicly available resources exist that catalog various attributes of genes. However, most of 
this information is just text descriptions and not built on a common “language”, so a common 
understanding of e.g. a description of a gene function or a pathway is difficult to find. 
However, some controlled vocabularies have been developed to address this problem. For 
example, GO represents a viable, and possibly long term, solution to the problem of 
inconsistent vocabulary. At least today GO is the most developed and used vocabulary for 
gene annotation, but other vocabularies like KEGG [215] are useful and has been popular, in 
the sense of analysing gene function. 
Further, the current GO structure may not be the final answer. It is evident that there also are 
biological relationships between terms of the different subontologies (MF, BP and CC). A 
recent software named GO Annotation Toolbox (GOAT) [217], connects the three 
subontologies to enable GO to cover more biological knowledge, which also enables a more 
consistent use of GO, and therefore provides new opportunities for biological reasoning. 
Most of the available GO tools use GO annotation data from a single public database. This has 
the advantage that the data is always as up to date as the database used. The disadvantage is 
that no single database offers a complete picture. For primary GO annotation data, the GO 
database (provided by the GO consortium [218]) is a comprehensive and up to date source 
since the contributing databases submit their data directly there. Other sources such as 
EntrezGene [163], derive their data from the GO database. In addition, EntrezGene curates 
these annotations, which in some situations may be useful. Our GeneTools database (Study 
III) obtains the GO annotations from EntrezGene, which we think is a good solution. 
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However, we also believe that using the GO database as the primary database can be a good 
solution if a “source” filter is available so that the users can choose which information from 
the GO database they want to use. A second problem is that certain pieces of information may 
also be imprecise or incorrect. For example, a large amount of the rat GO annotation 
associations are inferred exclusively from electronic annotations (i.e. without any expert 
human involvement). The vast majority of such electronic annotations are reasonably accurate. 
However, many such annotations are often made at a very high-level GO term which limits 
their usefulness. Furthermore, some of these inferences are incorrect. In our eGOn tool (Study 
III) we have implemented an “evidence” filter to solve this potential problem. To our 
knowledge, this is the only tool that offers this. A second potential solution can be to allow 
any type of weighting by quality of evidence in these GO tools, which is a limitation since 
experimentally derived annotations are more trustworthy than electronically inferred ones. 
 
3.4.3 Gene-class testing 
From microarray experiments, the investigators are often left with a large amount of 
unorganized findings. In response to the dual need to increase power to detect differential 
expression and to reduce the interpretive challenge that is posed by a long list of differentially 
expressed genes, gene-class testing has become a popular and widely accepted analytical tool. 
Gene classes are usually based on GO categories. Several gene-class testing methods and 
software packages are available, most of which use statistical tests to compare the number of 
genes in a class that are significant with the number that are expected under a particular null 
hypothesis. Several statistical tests for gene-class testing are offered in different GO tools. In 
our Study III (GeneTools [170]), we describe three different situations (master-target situation, 
mutually exclusive target-target situation and intersecting target-target situation), where 
different tests are used. 
Tests for the master-target situation are offered in almost all tools and the Fisher's exact test is 
what most tools use. However, just a few tools offer tests for the mutually exclusive target-
target situation, which we think is convenient when we want to look for differences between 
the representations of up- vs. down-regulated genes. In addition, to our knowledge we are the 
first to implement a test for the intersecting target-target situation. Such a test can be used to 
compare two gene reporter lists where a number of gene reporters are represented on both 
lists. In this way the intersecting target-target test can be used to investigate whether the GO 
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categories represented by these genes are over- or under-represented in the experiments behind 
the two lists. 
Studies II and IV show how such tests can be used in different situations and how the results 
can be used in further hypothesis generation. However, a general cautionary remark on the 
statistical tests for association between two gene reporter lists is that they are based only on 
the gene lists submitted to the tool, and the raw data underlying the statistical analyses 
producing the gene reporter lists are not submitted to most tools. This means that e.g. eGOn 
does not offer permutation based methods for addressing the dependence structure between the 
genes. The statistical tests in eGOn are thus based on the assumption that under the null 
hypothesis the genes on the lists (or subsets of the lists in the intersecting target-target 
situation) act independently, as is also commonly assumed in other GO-tools. 
A second important consideration when identifying statistically significant GO terms is the 
choice of the reference list of genes against which the P-values for each GO term in the results 
are calculated. Several tools (such as GOToolBox, GOstat, GoMiner, FatiGO, and GOTM) 
use the total set of genes in a genome as the reference or the total set of genes with GO 
annotations. Either of these may be an inappropriate choice when the input list of genes to 
these tools is a list of differentially expressed genes obtained from a microarray experiment, 
since the genes that are not present on a microarray do not have a chance of being selected as 
differentially regulated. The fundamental idea is to assign significance to various functional 
categories by comparing the observed number of genes in a specific category with the number 
of genes that might appear in the same category if a selection performed from the same pool 
were completely random. If the whole genome is considered as the reference, the pool 
considered when calculating the random choice includes all genes in the genome. At the same 
time, the pool available when actually selecting differentially regulated genes includes only 
the genes represented on the array used, since a gene that is not on the array can not be found 
to be differentially regulated. This represents an obvious contradiction of the assumptions of 
the statistical models used. Thus, in our GO tool eGOn, we use a master list (all reporters on 
array) as a reference list in the Master-Target test. 
 
3.5 86Rb+-uptake 
In Study I we used 86Rb+ to measure potential K+ uptake through the H+/K+-ATPase in cardiac 
myocytes. A sample of the cell suspension, containing 105 myocytes, was incubated at 37 C 
for 15 min (which was shown to be in the linear phase of 86Rb+-uptake) with 86Rb+. 86Rb+-
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uptake was measured in the absence and presence of Na+/K+-ATPase inhibitor ouabain and 
H+/K+-ATPase inhibitor SCH28080 which were added simultaneously with the 86Rb+. Most 
H+/K+-ATPase inhibitor are just active in an acidic environment. However, in this experiment 
we chose to use SCH28080 because it is active at neutral pH. 
In a control experiment the interaction of ouabain and SCH28080 on the 86Rb+-uptake was 
tested at concentrations giving submaximal inhibitions both separately and combined. We 
showed that the selective Na+/K+-ATPase inhibitor ouabain maximally reduced the 86Rb+-
uptake by about 70%, which agreed with previous results by Viko et al. [219]. In addition, we 
found that the H+/K+-ATPase specific blocker SCH28080 reduced 86Rb+-uptake by up to 70%. 
These observations suggest that at high concentrations, these agents directly or indirectly 
inhibit some common uptake mechanisms. At 1.0 X 10-4 M, however, SCH28080 did not 
interfere significantly with the 3H-ouabain binding to the Na+/K+-ATPase, which is in contrast 
with the marked effect of unlabelled ouabain. Thus, at concentrations up to 1.0 X 10-4 M, 
SCH28080 seems to selectively inhibit the H+/K+-ATPase without significantly inhibiting the 
Na+/K+-ATPase. At this concentration, the 86Rb+-uptake was reduced by about 25%, 
indicating that the H+/K+-ATPase may account for this fraction of the K+-uptake. However, we 
tested the interaction between SCH28080 and ouabain at 1.0 X 10-4 and 0.5 X 10-4 M, 
respectively, in order to minimize interaction of these two agents on 86Rb+-uptake 
mechanisms. Their inhibitory effects on the 86Rb+-uptake were almost exactly additive, 
indicating that at these concentrations SCH28080 and ouabain act on different uptake 
mechanisms. Thus these results are compatible with a contribution from the H+/K+-ATPase to 
the total 86Rb+-uptake. However, an accurate quantitative estimation of this contribution would 
depend upon a more exact knowledge of the selectivity of SCH28080 for the H+/K+-ATPase 
vs. the Na+/K+-ATPase than we obtained in this study. 
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4. Summary of results 
 
Study I 
- H+/K+-ATPase gene and protein expression was detected in heart tissue and localized 
to cardiac myocytes, by sequencing, rt-PCR, Western blotting, and immuno-
cytochemistry. 
- Competitive rt-PCR analysis indicated a significant up-regulation of the myocardial 
H+/K+-ATPase in heart failure after myocardial infarction, and the level of gene 
expression was related to infarction size. 
- Both ouabain and the selective H+/K+-ATPase inhibitor Schering 28080 reduced 86Rb+-
uptake at maximum specific inhibition, by 70 and 25%, respectively; the effects were 
additive. 
 
Study II 
- We identified differential expression of 153 and 147 genes, respectively, in coronary 
artery disease (CAD) or dilated cardiomyopathy (DCM) versus non-failing hearts. 
- Gene-class testing analysis of gene ontology (GO) biological process annotations 
indicated aetiology-specific patterns between CAD and DCM, primarily related to 
genes involved in catabolism and in regulation of protein kinase activity. 
- Gene expression classifiers were developed and used for class prediction of random 
samples of CAD and DCM hearts. Most confident discrimination was obtained when 
the classifier included up to seven genes with the highest t-statistics (corresponding to 
p<0.001). 
- The best classifier based on the AUC (0.89) measures correctly predicted group 
assignment in 16 of 20 samples, resulting in a test sensitivity of 0.750 and a specificity 
of 0.833. 
- The best classifiers frequently included Matrix metalloproteinase 3, Fibulin 1, ATP-
binding cassette, sub-family B member 1, and Iroquois homeobox protein 5. 
 
Study III 
- GeneTools is a web-service, providing access to a database that brings together 
information from a broad range of resources of gene information. 
- GeneTools provides three different tools: 
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I. NMC Annotation Tool, which offers annotations from several databases like 
UniGene, Entrez Gene, SwissProt and GeneOntology, in both single- and batch 
search mode. 
II. GO Annotator Tool, where users can add new gene ontology (GO) annotations to 
genes of interest. Such user-defined GO annotations can be used in further 
analysis or exported for public distribution. 
III. eGOn, which is a tool for visualization and statistical hypothesis testing of GO 
category representation. 
- As the first GO tool, eGOn supports hypothesis testing for three different situations 
(Master-Target situation, Mutually Exclusive Target-Target situation, and Intersecting 
Target-Target situation). 
- An important additional function is an evidence-code filter that allows users to select 
the GO annotations for the analysis. 
 
Study IV 
- At all time points, three genes; Natriuretic peptide-precursor A, Interferon regulatory 
factor 3 (Irf3), and D-serine modulator-1, were up-regulated in CHF, and one gene, 
RAD23a homolog, in response to exercise. 
- Irf3 may be a potential drug target, since it is likely to mediate the effects of 
peroxisome proliferator-activated receptors, which control fatty-acid oxidation in 
cardiac hypertrophy. 
- Genes involved in fatty-acid metabolism were down-regulated in CHF, but not in 
response to exercise. 
- Physiological hypertrophy was associated with less comprehensive changes in gene 
expression, indicating that post-transcriptional and post-translational regulation may be 
more important than in pathological hypertrophy. 
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5. Results and discussion 
 
5.1 Functional genomics in cardiovascular research 
Since human cardiac tissue is less accessible than e.g. tumor material, expression profiling has 
been performed to a lesser extent in human cardiac disease. The first cardiac expression 
profiles were based on analyses of expressed sequence tags (ESTs) obtained from cDNA 
libraries, leading to catalogues of genes expressed in normal or hypertrophied hearts [220-
222]. These studies were followed by microarray analyses identifying genes (gene discovery) 
with differential expression levels in failing hearts. More recently, attempts were conducted to 
classify groups (supervised or unsupervised methods) of patients with end-stage heart failure 
based on their expression profile. In relation to all this, our Studies II and IV are natural 
further developments of what is previously done in this field of cardiovascular functional 
genomics. 
 
5.2 Heart failure and gene expression 
Researchers have long been interested in the development, progression and treatment of HF. 
Mouse and rat models of HF and cardiovascular disease have been created to enable studies of 
the disease mechanisms, devices to assist the heart in its pumping activity have been designed, 
and drugs to boost heart function have been developed. However, as of yet, the underlying 
mechanisms of heart disease remain uncertain and the therapies to treat it are still imperfect. 
Seeking to gain a better understanding of HF and find new ways to diagnose and treat it, we 
(by the studies in this thesis) and several others have examined the activity of genes in failing 
hearts. We aimed at studying both the causes and effects of heart failure, and one of the ways 
to do that is to look at changes in gene expression. For example, in Study I, we used standard 
rt-PCR and competitive rt-PCR to detect regulation of expression of H+/K+ in relation to heart 
infarction and during development. However, the more recent development of the DNA 
microarray technology enabled us and others to simultaneously study gene expression of tens 
of thousands of gene at once. One of our main aims in Study II and IV was to look for gene 
expression patterns in “normal” hearts versus diseased hearts, compare “acute” versus 
“chronic” phase and look for aetiology specific differences. 
Like in most other studies we found that a set of genes and the molecular functions that they 
contribute to are regulated in the same way in different forms of HF diseases, reflecting a 
reaction to the pathological stimuli. For example, a high proportion of the differentially 
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expressed genes in the HF samples we measured in Study II and IV were related to e.g. cell 
communication, signal transduction, metabolism, transcription and development. Among the 
genes differentially expressed in HF we found an over representation of differentially 
expressed genes related to e.g. response to stress, defense response and inflammatory 
response, indicating that these processes are important in defining the HF specific response. 
Several other reports have shown similar patterns. For example, Yang et al. [223] was one of 
the first to publish gene discovery results from microarray data. They used high-density 
oligonucleotide arrays to explore changes in expression of ~7000 genes in 2 non failing and 2 
failing human hearts with diagnoses of end-stage ischemic and dilated cardiomyopathy, 
respectively. They reported altered expression of cytoskeletal and myofibrillar genes, genes 
responsible for degradation and disassembly of myocardial proteins, genes involved in 
metabolism, genes responsible for protein synthesis, and genes encoding stress proteins. Like 
in this work, many authors have published “lists” of genes with altered expression in HF of 
e.g. CAD and DCM [37,224-230], where most studies involved small sample sizes and binary 
comparisons such as failing and non failing hearts. In addition, several papers have described 
the same global gene expression pattern in rodent models of HF [29,231-234]. Common for all 
these and our studies of HF, is an observed general change in expression levels of genes 
encoding cytoskeletal and extracellular matrix (ECM) proteins, as well as proteins involved in 
apoptosis and intracellular signaling, energy and lipid metabolism, cell communication and 
calcium-handling pathways. Together these studies, using genome wide gene expression 
arrays and making “lists” of differentially expressed genes which is a relatively easy but 
“rough” method to create general hypotheses, provided insights into novel genetic pathways 
and therapeutic targets. This may serve as the basis for studies involving molecular signature 
analysis. However, we believe that more sophisticated data analysis methods will be used to 
extract information from microarray data in the future. Such methods may be classification 
(e.g. supervised learning or PCA), connection to functional information (e.g. GO or KEGG), 
and modeling by systems biology approaches. The extended use of GO information in gene-
class testing using statistical hypothesis testing has been very popular, but not many groups 
working with cardiovascular systems have published work using such methods and few 
attempts have been made to characterize genome-wide differences in gene expression patterns 
between e.g. CAD and DCM hearts. In our Study II and IV we extensively used such methods 
and this will be discussed in the next chapters. 
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5.2.1 Pathological and physiological hypertrophy signals 
Cardiac hypertrophy responses can be found both in a physiological and pathologic setting, 
but the hypertrophy responses are not homogenous as shown in Study IV. Whereas 
physiological hypertrophy is characterized by eccentric growth, pathologic remodeling may be 
of either eccentric or concentric nature, depending on whether it is in response to pressure or 
volume overload [22]. Although the pathologic hypertrophy process is initially compensatory 
to an increased workload, it frequently progresses into detrimental remodeling and cardiac 
dysfunction, heart failure, arrhythmia and sudden death [235]. For example, in our MI model 
(Study IV) we measured that LV weight had increased by 45% at day 7 (p<0.01), and further 
to 53% (p<0.01) after 92 days, compared to sham animals. In addition previous studies in our 
laboratory have shown increased diastolic LV diameter, LV pressure and reduced peak dP/dt, 
peak –dP/dt and peak-systolic pressures already one week after coronary artery ligation. 
Together, this indicates a hypertrophy response already after 1 week [75,177,178]. On the 
other hand, cardiac hypertrophy induced by exercise training is considered a favorable 
adaptive response of the heart to regular physical activity and increase in bodily demands 
[236], and is characterized by increases in left ventricular (LV) chamber size, wall thickness 
and mass [237]. Several studies in our laboratory have demonstrated that the described 
exercise program elicits cardiac hypertrophy, both at the organ and cellular level 
[185,187,188,238,239]. LV weights increased by ~10% and 20-30%, whereas LV cardiac 
myocyte lengths increased ~6% and 10-15%, after 4 and 8 weeks of exercise, respectively, 
while a single exercise bout does not elicit any detectable increase in LV mass or myocyte 
size. Moreover, the cardiac growth in this exercise model is also associated with improved 
contractile function and Ca2+ handling by the cardiac myocytes [187,188,238,239]. Thus, it is 
an established, well verified and good model to study physiological hypertrophy of the heart. 
The fact that physiological hypertrophy does not associate with dysfunction, but rather with 
sustained or improved function, leads to the question of what differentiates physiological from 
pathologic cardiac hypertrophy. It has been suggested that stimuli-specific hypertrophy 
responses may be associated with distinct molecular signatures [240,241]. 
In Study IV, we compared gene expression pattern from physiological (exercise training) and 
pathological (MI) hypertrophy models. One of the striking results was that a significantly 
lower number of differentially expressed genes was found in response to physiological 
compared to pathological hypertrophy. In addition there were no large differences in the 
numbers of differentially expressed genes during the studied time period in response to 
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physiological hypertrophy as compared to pathological hypertrophy where a significantly 
higher number of genes were differentially expressed in the acute phase vs. the chronic phase. 
This corresponds with other studies [29] and may be explained by the physiological stimulus 
being weaker than the pathological stimulus. Moreover, with the fact that relatively few genes 
are differentially expressed in response to physiological hypertrophy, our results (Study IV) 
indicate that post transcriptional processes, including translation regulation are important in 
development of physiological hypertrophy. Recently, it has been shown that activation of the 
IGF-1/ Phosphoinositide 3-kinase/Akt pathway is important for induction of physiologic, but 
not pathologic hypertrophy of the heart. The action of this pathway is mainly to increase 
ribosomal activity and protein synthesis without inducing a greater expression of hypertrophy-
related genes; thus, improving translational efficiency [63]. Moreover, our observation in 
Study IV that genes related to protein amino acid dephosphorylation were over represented 
among the differentially expressed genes in response to physiological hypertrophy, supports 
the hypothesis that other factors than mRNA abundance may be important. 
In Study IV the hypertrophy marker gene Natriuretic peptide precursor A (Nppa/ANF) was 
found to be up-regulated at all time points in response to MI. This correlates well with 
previous data obtained in our lab from the same rat MI model [177] using competitive rt-PCR 
for detection of gene expression. We found the hypertrophy marker Nppa/ANF to be up-
regulated at the first two time points (1 and 4 hours after a single exercise bout), but not later 
in the hypertrophy process. Increased mRNA Nppa/ANF levels have also been found in 
response to some “chronic” training models, for example rats subjected to swimming 
[242,243], dogs subjected to a treadmill training program [244], and mice subjected to a wheel 
running program [245]. However, similarly to our study, in rats subjected to weeks of regular 
treadmill running [244,246,247] no induction of mRNA Nppa/ANF levels were found. 
Together, these results indicate that increased ANF expression is mediated at the 
transcriptional level as an early response to exercise and therefore the main signal may be the 
acute mechanical stretching of cardiac myocytes and not the hypertrophy itself. 
To further identify biological processes differently represented between physiological and 
pathological hypertrophy, we looked for functional clusters among the differentially expressed 
genes, at different time points after MI and exercise training. The main finding was that genes 
related to fatty acid metabolism were down-regulated at all stages of MI, suggesting a switch 
in metabolism to carbohydrate metabolism. This was not seen in response to physiological 
hypertrophy. The switch in metabolism is a well known response to heart disease, however in 
 - 57 -
this study we show that it is a very early response to MI and that it continues during the whole 
disease process until HF is reached. It has been suggested that PPARs constitute the main 
control mechanism for myocardial metabolism by transcriptionally regulating genes encoding 
enzymes involved in fatty acid and glucose utilization [248], but a recent study [249] indicates 
a dissociation between gene and protein expression related to these processes. However, it is 
still a rationale for metabolic therapy to remedy cardiac hypertrophy and dysfunction in 
cardiac disease [250]. The possible role of the PPARs in the control of cardiac energy 
metabolism makes these regulatory pathways attractive targets for metabolic therapy. 
Interestingly, in addition to Nppa we found Interferon regulatory factor 3 (Irf3) to be 
overexpressed at all time points after MI (Study IV). Irf3 is a key player in the initial 
triggering of interferon gene transcription [251]. Moreover, it has been suggested that Irf3 may 
mediate the pro-apoptotic and anti-proliferative effects of peroxisome proliferator-activated 
receptors (PPARs) [252]. Little is still known about Irf3 in cardiac hypertrophy, but our results 
indicate a potentially important function. This should be further explored, and may be a 
subject for a follow up study. 
 
5.2.2 Aetiology specific expression patterns 
In our Study II we detected CAD and DCM aetiology-specific patterns by linking results from 
the gene expression analysis to GO annotations. First, for both groups of samples we found an 
over-representation of differentially expressed genes involved in cell communication, response 
to stress, response to external biotic stimulus, defense response, immune response and 
inflammatory response. However, some biological processes were over-represented in either 
CAD or in DCM and our main findings were that significantly more genes involved in 
catabolism were differentially expressed in CAD compared to DCM, which is consistent with 
catabolic/anabolic imbalance in CAD [253]. Moreover, a separate comparison of up-regulated 
and down-regulated genes was performed. A significantly higher number of genes involved in 
catabolism were up-regulated in CAD hearts compared to DCM hearts. Among 12 genes 
exclusively up-regulated in CAD, we found a sub-cluster of four genes involved in lipid 
catabolism, apolipoprotein C-II, (APOC2), lipoprotein lipase (LPL), phospholipase C, beta 1 
(PLCB1) and phospholipase C, gamma 2 (PLCG2). In contrast, lipase, member H (LIPH) and 
phospholipase C, delta 1 (PLCD1) were down-regulated only in DCM. This indicates that 
lipid catabolism and lipid signaling is stimulated in end-stage CAD but not in DCM. This 
correlates with the results from Study IV, where we found an overrepresentation of genes 
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related to fatty acid metabolism (almost all down-regulated) in response to heart infarction, 
indicating a switch from lipid to carbohydrate metabolism. 
During development of hypertrophy, phospholipase C (PLC) is increased, and in the failing 
heart PLC isozymes are decreased [254]. Normal, exercise-induced cardiac growth is mainly 
regulated by the growth hormone/IGF axis through the PI3K/Akt pathway. In contrast, 
pathological cardiac growth is triggered by autocrine and paracrine neurohormonal factors that 
signal through the Gq/phospholipase C pathway, leading to increased cytosolic calcium and 
PKC activation. In Study II we found IGF1 up-regulated in CAD, but not in DCM hearts, 
suggesting activation of a compensatory effect through the growth hormone/IGF pathway in 
end-stage CAD. However, this signal seems to be attenuated by an activation (up-regulation in 
both groups) of the phosphatase and tensin homolog (TPEN), which blocks signaling 
downstream of this pathway. Hence, our results indicate that the PLC pathway is activated in 
end-stage CAD, but not in DCM. These results are supported by the functional clustering, 
which shows that more genes regulating protein kinase activity are differentially expressed in 
DCM than CAD hearts. Among the genes regulating protein kinase activity that were 
differentially expressed in DCM but not in CAD, we found a sub-group of up-regulated genes, 
which inhibit protein kinase activity or cell division. Thus, an alternative to the 
Gq/phospholipase C pathway for hypertrophy may be active in end-stage DCM. 
In this way Study II and IV have shown how it is possible to use gene-class testing methods 
and GO information to generate new hypotheses. Not many authors have yet described the use 
of such methods in cardiovascular research, but some good examples exist. For example, 
Barth et al. [255] used FatiGO [256] to look for regional gene expression patterns and 
significant associations of Gene Ontology terms within groups of genes expressed in left 
ventricular (LV) versus expression in right ventricular (RV) myocardium of human and 
mouse. Among other results they found that with respect to biological processes, functional 
groups related to cell-cell communication and response to external stimuli were more 
abundant in RV, while metabolic and energy-driving processes were over-represented in LV. 
Another example is a study published by Kong et al. [29] who used the ErmineJ software 
[257] to identify enriched GO classes in different rat models of physiological (exercise) and 
pathological (Dahl salt-sensitive rats) hypertrophy and heart failure. They found that during 
pathological hypertrophy, genes associated with the apoptosis pathway showed statistically 
significant over representation. In addition the authors suggested that gene clusters associated 
with glucose/insulin signaling, protein biosynthesis, and epidermal growth factor (EGF) 
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signaling pathways may be involved predominately during physiological hypertrophy. All 
together these results fit with what we found in Study II and IV. 
 
5.2.3 Classification of heart disease using microarray data 
In the past, supervised learning methods have mainly been used to predict cancer subtypes 
prognosis and treatment outcome [258-261], and just a few examples on heart failure are 
known. Kittleson et al. [262] were the first to use application of supervised learning analysis in 
cardiovascular disease. They identified a gene expression profile (best classifier included 90 
genes) that differentiates the two major forms of cardiomyopathy, ischemic and non ischemic. 
A 16-sample training set was used to develop a prediction rule which was then tested in nine 
independent samples, including seven from a different institution. Their results showed that 
the aetiology signature performed perfectly in non ischemic samples (specificity 100%) but 
only identified one of three ischemic samples correctly (sensitivity 33%). In our Study II we 
obtained classifiers (consisting of 7 genes) using methods based on rough sets, to predict 
random samples of coronary artery diseased and dilated cardiomyopathic hearts. Like 
Kittelson et al. we were not able to predict all the samples to the correct group. Our best 
classifier predicted 16 of 20 samples correctly which gives a sensitivity of 0.750, a specificity 
of 0.833 and an AUC value of 0.89. This is not perfect and we believe the main reason for this 
is the limited number of samples. Another possible limitation is the biological variation 
between the samples in the groups, and the difficulty to obtain good quality RNA from human 
heart tissue samples. Similar studies on classification of cancer samples have given even better 
results [258,263,264], but in the some case of cancer much larger populations of samples are 
available and the samples may be more similar within each group. 
However, taking this limitation in account, both studies indicate that microarray gene 
expression analysis may become an important complement to current standard methods, by 
providing more precise molecular diagnoses, and by sub-grouping existing disease categories 
into clusters with more accurate predictions of prognosis and response to treatment. For HF 
patients, the clinical benefit of expression profiling may not lie within classification at end-
stage, but earlier in the course of the disease, where treatment strategies need to be improved. 
Further, microarray data may be incomplete and variable across platforms and between 
laboratories, if standardized protocols for hybridization and data acquisition are not used 
[193]. However, a central question is whether the predictive microarray data set can be used to 
extract a limited number of relevant genes whose expression levels convey the same 
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information as the whole set. Recently, Lossos et al. [264] evaluated a 6-gene-set QRT-PCR 
assay against original microarray data which predicted the clinical course of large-B-cell 
lymphoma and found that this 6-gene set was sufficient to predict survival. Thus, our 
assumptions for the future is that whole genome microarrays will be used to establish 
classifiers for prediction of e.g. disease or disease states, but for clinical use “focused” 
microarrays in e.g. microtiter plates, with just a limited numbers of probes, or a set of RT-PCR 
assays may be preferred. 
In contrast to our approaches in Study II where the number of genes is reduced, unsupervised 
learning methods usually uses all data points for the experiments. The popularity of clustering 
and unsupervised analysis is also reflected in papers describing microarray experiments on 
HF, and recently some attempts have been made to characterize small groups of patients with 
end-stage HF based on hierarchical clustering of gene expression profiles. It is also possible to 
find attempts to use unsupervised methods to “classify” CAD and DCM. For example, 
Steenman et al. [229] were able to make distinct clusters of patients who were awaiting urgent 
cardiac transplantation, by hierarchical clustering analysis, but they were unable to identify 
specific clusters for the different aetiologies. A similar approach was used by Barrands et al. 
[224] where DCM hearts were successfully clustered against non failing hearts. Together these 
findings suggest that gene expression can be correlated to clinically relevant parameters in 
patients with HF. However, since the studies were focused on clustering (gene discovery), the 
observations could not be applied prospectively to identify and validate a gene expression 
signature with the intention to distinguish subjects based on relevant clinical parameters. This 
emphasizes the need for studies focused on molecular signature analysis. In contrast, our 
classifiers (Study II) selected a small number of genes whose expression levels distinguish 
between CAD and DCM, thus demonstrating, at least in this case, the feasibility of using 
microarray data and class prediction for studying HF pathobiology as compared to class 
discovery methods. 
In relation to the results obtained in our Study II, a potentially clinically relevant follow-up 
study could be to classify different aetiologies of cardiomyopathy. This can help in the process 
of early diagnosis and correct selection of treatment. Another follow-up study may be to 
genotype different sub groups of cardiomyopathy patients with genome wide SNP microarray 
(arrays with up to 500K are now available). It is already known that genetic variation is 
involved in cardiomyopathy and arrhytmias [265,266]. 
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5.3 H+/K+-ATPase activity and function in myocytes 
During experiments on uptake of potassium and intracellular alkalization Falck et al. 
suggested that proton transport during hyperosmolal stress may be potassium dependent 
[267,268]. We thus anticipated that there might be another mechanism than the Na+/K+-
ATPase and the Na+/K+/2Cl- co-transporter that could translocate K+ into the cardiac 
myocytes. In previous studies, only Northern blot and cytochemical analysis had indicated 
presence of the gastric H+/K+-ATPase in rat myocardial tissue [269] and atrial myocytes 
[270,271], and there was no other report of similar findings at both RNA, protein and 
functional levels, in the left ventricle. 
A study (Study I) to further investigate these indications was thus started. For the first time we 
have been able to show the presence of functional protein and gene expression of the gastric 
H+/K+-ATPase in rat heart and myocytes. We also showed regulation during development and 
in heart failure, indicating that the H+/K+-ATPase may play a crucial role in the mechanical 
and electrophysiological properties of the rat heart. Moreover and most importantly, we 
investigated whether the H+/K+-ATPase could account for a significant part of the 86Rb+-
uptake in cardiac ventricular myocytes. Our study suggests a contribution from the H+/K+-
ATPase of about 25% of total 86Rb+-uptake. Although its relative role cannot easily be 
translated into in vivo K+-influxes, our data suggest that the gastric H+/K+-ATPase could 
contribute significantly to the regulation of myocardial K+ and H+ homeostasis. This may be 
particularly important in myocardial ischaemia and acidosis, provided that the H+/K+-ATPase 
activity is regulated as in vascular smooth muscle cells, where McCabe & Young [272] 
demonstrated that inhibitors of H+/K+-ATPase caused a rapid and marked decline in pHi and a 
marked depression in K+ content. Their observations suggested a significant potential for 
maintenance of H+ and K+ gradients in vascular smooth muscle cells, which according to our 
results, also may be true in cardiac myocytes. However, in a recent publication, Yenisehiril et 
al. [273] investigated the effects of three specific H+/K+-ATPase inhibitors (Omeprazole, 
lansoprazole and SCH28080) on the contractile and chronotropic properties of isolated rat 
atrium. The possible changes in atrial action potential configuration were also studied. 
Yenisehiril et al. found that all three different H+/K+-ATPase inhibitors induced positive 
inotropic and negative chronotropic effects in the rat atria, in vitro. They also showed that 
these concentration dependent, reversible and reproducible effects seem not to be mediated by 
well known pathways that enhance contractility such as inhibition of Na+/K+-ATPase and 
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phosphodiesterase type III or activation of β-adrenoceptors. None of the pharmacological 
agents used in this study attenuated the cardiac effects of proton pump inhibitors. Therefore 
both they and we (Study I) suggest that H+/K+-ATPase accounts for K+-uptake and has a 
possible role in intracellular pH regulation of cardiomyocytes. However, intracellular 
acidification is known to reduce force of contraction in cardiac muscle cells [274] and if 
intracellular acidosis reduces force of contraction, inhibition of H+/K+-ATPase is expected to 
decrease the amplitude of atrial contractions. 
In our study (Study I) we demonstrated that SCH 28080 did not interfere significantly with the 
3H-ouabain binding to the Na+/K+-ATPase in rat cardiomyocytes and we concluded that SCH 
28080 and ouabain act on different 86Rb+-uptake mechanisms. These observations are 
compatible with the recent findings by Yenisehiril et al. [273]. They found that the cardiac 
effects of proton pump inhibitors operate through a mechanism different from Na+/K+-ATPase 
inhibition and they conclude that compounds known to inhibit H+/K+-ATPase increased 
contractility, decreased heart rate and exerted antiarrhythmic actions in isolated rat atria. 
Yenisehiril et al. also suggested that these effects appeared to be mediated by inhibition of 
myocardial H+/K+-ATPase and seem to be a result of prolongation of action potential duration. 
Moreover, a recent publication by Kemi et al. [86] concludes that H+/K+-ATPase does not 
contribute significantly to pHi maintenance. However, the complete role of the H+/K+-ATPase 
in pH-regulation and/or cell volume regulation has not yet been completely determined, and 
may be a subject to a potential follow up study. 
 
5.4 Gene expression versus protein expression and molecular function 
In our Studies II and IV, we have measured gene expression and made hypotheses of on the 
biological processes in the myocardial cells. However, it is not necessarily true that gene 
expression results in active protein. Translation of individual mRNA species into their 
encoded proteins is regulated at multiple levels: transcriptional control, RNA processing 
control, RNA transport control, translation control, mRNA degradation control and protein 
activity control, introducing possible discrepancies between mRNA and protein levels. As 
discussed earlier (regarding Study IV), this may be an important difference between the 
pathological and physiological hypertrophy response. However, as mRNA is eventually 
translated into protein, one might assume that there can be some sort of correlation between 
the level of mRNA and that of protein [275]. Attempts to correlate protein abundance with 
mRNA expression have had variable success, but several studies show a positive correlation in 
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the range from r = 0.48-0.76 [260,276]. This implies that there, at least in general, is a 
correlation between mRNA and protein abundance. In our Study I we show that gene 
expression and protein expression correlated at least for one gene and protein (H+/K+-
ATPase). A wide assessment of protein function in experimental situations like this is, 
however, not possible with today’s technical limitations. In the future proteomics may become 
more important and comparisons more informative, as larger datasets of both mRNA and 
proteomic measurements are obtained. It is also possible that other applications like tissue 
arrays and cell arrays (e.g. si RNA) will be available for the verification of hypotheses 
generated from genomic approaches and help to obtain a more complete understanding of how 
a cell works. 
 
5.5 From genomes to systems 
The present studies are examples of how research in functional genomics can be performed, 
switching between detailed functional studies of single genes/protein and high-throughput 
analysis and extensive use of bioinformatics tools. However, recent advances in the “omics” 
technologies, scientific computing, and mathematical modeling of biological processes will 
start to fundamentally impact the way we approach cardiovascular diseases and research. 
During the recent years we have witnessed the development of genome-scale functional 
screens, protein microarrays, databases and algorithms for “data-mining” and “text-mining”. 
Altogether, this enables unprecedented descriptions of complex biological systems, which are 
testable by mathematical modeling and simulation. While the methods and tools are 
advancing, it is their iterative and combinatorial application that defines the systems biology 
approach [277], which now is the new “hype” in biology and medicine. Systems biology deals 
with understanding and depicting the complex and dynamic processes inside cells or organs. 
The wealth of data on different cell elements or functions, which were gathered at different 
levels of the life processes (genome, proteome, metabolome) may be put in a meaningful 
overall context and modelled on a computer, so that simulations and predictions may reduce 
the use of laboratory experiments. Through contextual understanding of the molecular 
mechanisms of disease, a systems approach may facilitate the identification and validation of 
therapeutic modulation of regulatory and metabolic networks, and hence help identify targets 
and biomarkers, as well as “off-target” effects and side effects of new drugs. In cardiovascular 
research, models of heart cells are becoming highly sophisticated and have benefited from four 
decades of interaction between experimental and simulation approaches [278]. Biological 
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simulation in cardiovascular research is now being applied over a wide range of pathways, 
cells and systems. The role of in silico biology in cardiovascular and pharmaceutical research 
is likely to become increasingly prominent as a result of the exploration of data generated 
through genomics and proteomic approaches. 
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6. Conclusions 
- Gene expression classifiers could be used for class prediction of random clinical 
samples of CAD and DCM hearts. Best classifiers frequently included Matrix 
metalloproteinase 3, Fibulin 1, ATP-binding cassette, sub-family B member 1 and 
Iroquois homeobox protein 5. 
- Analyzing gene expression at the level of gene ontology (GO) instead of at the level of 
single genes, detected the involvement of several biological processes e.g. 
transcription, metabolism, catabolism, muscle contraction, neurophysiological 
processes, defense response, and signal transduction, in myocardial hypertrophy and 
congestive heart failure. 
- Gene-class testing analysis of GO biological process annotations indicated aetiology-
specific patterns between CAD and DCM, primarily related to genes involved in 
catabolism and in regulation of protein kinase activity. 
- A main difference in gene expression patterns between the models of pathological and 
physiological hypertrophy was the down-regulation of genes involved in fatty-acid 
metabolism in response to CHF, but not to exercise training. 
- Physiological hypertrophy is associated with less comprehensive changes in gene 
expression than pathological hypertrophy, indicating that post-transcriptional and post-
translational regulation may be more important. 
- GeneTools is an “all in one” annotation tool, where the users can rapidly extract gene 
annotation data for thousands of genes or clones. eGOn includes tools for gene class 
comparison, that can perform hypothesis testing base on the representation of GO 
categories between gene reporter lists. 
- H+/K+-ATPase is expressed in cardiac myocytes and accounts for 25% of the K+-
uptake in isolated ventricular cardiomyocytes, suggesting a role in the regulation of 
intracellular pH. 
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